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What lies behind us and what lies before us are 
tiny matters compared to what lies within us 
Ralph Waldo Emerson 
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ABSTRACT 
Type 2 diabetes is a progressive disease with deterioration of glycaemic control over 
time in association with loss of endogenous insulin secretion. As a consequence of this, 
sulphonylureas (SU), which exert their mode of action by stimulating the pancreatic β-
cells, are expected to be less effective with longer duration of diabetes. Thus SU is 
often withdrawn when insulin is started and SU is less frequently added to insulin and 
metformin in patients not reaching glycaemic goals. The aim of the work presented in 
this thesis was to investigate different aspects on the use of SU in patients with diabetes 
exceeding more than 5-10 years. 
In Study I glycaemic control and β-cell function were monitored during a period of SU 
withdrawal in 25 patients, median diabetes duration 19 (8-29) years and on combined 
SU + insulin for > 5 years. In 80% glycaemic control deteriorated after SU withdrawal. 
Diabetes duration was positively correlated to the increase in fasting plasma glucose, 
i.e. in this group of patients a longer diabetes duration indicated more benefit of SU. 
In Study II changes in HbA1c and β-cell function, assessed as C-peptide/glucose ratio, 
were observed at two time points, ten years apart, in patients who had attended the 
Diabetes Day Care Centre in 1997/1998. Of 462 patients, 171 attended the follow-up 
visit ten years later. Possible relations between SU treatment and changes in β-cell 
function were studied. HbA1c and β-cell function decreased but long-term use of SU 
was not associated with a more pronounced decline in β-cell function. It was concluded 
that these observations did not support the concept that SU is harmful to the β-cell. 
Study III was performed to test whether SU still can be effective after > 10 years of 
diabetes. This randomized, placebo-controlled, double-blind, cross-over study included 
43 patients, median diabetes duration 16 (10-30) years, with on-going metformin and 
insulin therapy. During two treatment periods of 12 weeks, separated by a washout 
period of six weeks, patients were given placebo/glimepiride in a randomized order as 
add-on therapy. No changes in baseline therapy were made except for insulin reduction 
if needed. HbA1c and changes in insulin requirement were primary outcomes. With 
glimepiride, HbA1c decreased from 7.0% to 6.4% (63-56 mmol/mol) while no change 
was observed during the placebo period. The insulin dose was reduced in 23 patients 
(median change 29%) with glimepiride addition. No severe hypoglycaemia occurred 
but 22 patients reported 124 minor hypoglycaemias, 74% of them occurring during the 
glimepiride period. Nocturnal glycaemia was monitored with CGMS at the end of each 
treatment period. In 15 patients on glimepiride episodes of glucose < 3.1 mmol/l were 
observed; and in six patients when placebo was added. It was concluded that addition 
of glimepiride to insulin + metformin therapy can lower HbA1c and reduce insulin 
requirement despite a long duration of diabetes. 
In Study IV the accuracy of nocturnal CGMS monitoring was assessed after 48 and 72 
hours in 14 patients on combined oral and insulin therapy. The study was conducted in 
the early era of CGMS and the sensor was the first model on the market. Nocturnal 
reference P-glucose values were assessed seven times and compared to sensor readings. 
In a Clark Error Grid model 100% of values were within zones A+B after 48 hours 
while only 44 % were in zone A and 7% in the unacceptable zone D after 72 hours. 
With the sensor used in the study the accuracy of CGMS thus deteriorated over time. 
Conclusion: The decline in β-cell function over times varies considerably between 
patients. Sulphonylureas are effective when combined with insulin and metformin in 
many patients with long-standing type 2 diabetes; and long-term treatment with SU is 
not associated with are a pronounced decline in β-cell function. 
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LIST OF ABBREVIATIONS 
ACCORD Action to control cardiovascular risk in diabetes 
ADA American Diabetes Association 
ADOPT A diabetes outcome progression study 
ADVANCE Action in diabetes and vascular disease: preterax- and diamicron-
modified controlled evaluation 
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IGT Impaired Glucose Tolerance 
i.v. intravenous 
IVGTT intravenous glucose tolerance test 
JDS HbA1c Japan Diabetes Society standardized glycohaemoglobin 
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NGSP National Glycohaemoglobin Standardization Program 
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NHANES National Health and Nutrition Examination Survey 
SMPG self-monitoring of plasma glucose 
SU sulphonylurea 
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UKPDS United Kingdom Prospective Diabetes Study 
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INTRODUCTION 
 
Type 2 diabetes is one of the most common chronic diseases in the world and the number of 
people with the diagnosis continues to increase [Whiting et al. 2011]. It is estimated that 366 
million people worldwide had diabetes in 2011 and it is assumed that by 2030 around 552 million 
people will have the diagnosis. Ninety percent of these people have type 2 diabetes and 80% live 
in low- and middle-income countries [IDF 2011]. 
 
Patients with diabetes risk developing both micro- and macrovascular complications [Zimmet et 
al. 2001] and persons with type 2 diabetes have a more than two-fold increased risk of death from 
cardiovascular diseases (CVD) than those without diabetes [Saydah et al. 2001]. The risk of 
complications is related to glycaemia, measured by HbA1c, as has been shown in prospective 
studies both in type 1 [DCCT 1993] and type 2 diabetes [UKPDS 1998; Shichiri et al. 2000] 
 
In the United Kingdom Prospective Diabetes Study (UKPDS) patients with newly diagnosed 
type 2 diabetes were allocated to conventional or intensive treatment with insulin or sulphonyl-
urea (SU) and followed for no less than 10 years [UKPDS 1998]. The overall HbA1c achieved was 
0.9% lower in the intensive-treatment group than in the conventional group (7.0% vs. 7.9%), and 
this was associated with a significant reduction of microvascular complications and a trend 
towards a reduction of macrovascular complications. In addition, epidemiological analyses from 
UKPDS revealed that the risk of complications was strongly related to previous hyperglycaemia 
and that any reduction in HbA1c of 1%, regardless of starting value, was associated with a 21% 
decrease in the risk of any diabetes-related endpoint [Stratton et al. 2000]. 
 
In 2008 two large trials - ACCORD [Gerstein et al. 2008] and ADVANCE [Patel et al. 2008] - 
were presented. They both sought to further study whether intensive glucose control could reduce 
the risk of CVD events in patients with type 2 diabetes. However, neither study showed that 
lowering HbA1c below 7%, i.e. IFCC 53 mmol/mol, was beneficial in reducing macrovascular 
complications or mortality; indeed, mortality actually increased in the intensive group in the 
ACCORD study. A Cochrane review published in 2011 concluded that intensive glycaemic 
control had no significant effect on all-cause and cardiovascular mortality but reduced the risk of 
microvascular complications [Hemmingsen et al. 2011]. However, a long-term follow-up of the 
patients who had participated in the UKPDS demonstrated that, despite an early loss of the 
difference in HbA1c between conventional and intensive treatment groups after the end of study, 
there were emergent and significant reductions in myocardial infarction and total mortality for 
those receiving intensive therapy from start [Holman et al. 2008]. A continued reduction of 
microvascular risk was also confirmed in this analysis. These observations have been referred to 
as a legacy effect, indicating that intensive glucose control starting at the time of diagnosis is 
associated with a decreased risk of diabetes complications, emphasizing the importance of early 
and stringent interventions in the treatment of type 2 diabetes. 
 
Even if treatment of hyperglycaemia is important, especially to reduce microvascular complica-
tions, multifactorial treatment addressing not only hyperglycaemia but also hypertension and 
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hyperlipidaemia, seems to be very important for protection against vascular complications, as was 
shown in the Steno-2 study [Gaede et al. 2008]. 
 
Type 2 diabetes is a progressive disease with a worsening of glycaemia over time in most patients. 
The proposed underlying mechanism is a continuing decline in β-cell function resulting in a loss 
of insulin secretory capacity [UKPDS 1995; Levy et al. 1998]. This induces a need for intensifica-
tion of glucose-lowering therapies [Turner et al. 1999; Koro et al. 2004], which was successful as 
shown in a recent observational study where increased treatment with oral drugs and insulin 
maintained glycaemic control over five years [Best et al. 2012]. 
 
When intensifying glucose-lowering therapy with insulin, one problem is the risk of hypo-
glycaemia [Zhang et al. 2009; Best et al. 2012]. This is also true but to a smaller extent for SU 
[Leese et al. 2003]. Hypoglycaemia has received limited attention as a problem in type 2 diabetes, 
but there are reasons to question this [Frier 2002]. First, the risk of hypoglycaemia increases with 
longer diabetes duration [Henderson et al. 2003]. Secondly, there is currently much emphasis on 
adherence to strict glycaemic goals in type 2 diabetic patients with an increased use of insulin. 
This in turn increases the frequency of hypoglycaemia [Donnelly et al. 2005]. Thirdly, since the 
prevalence of type 2 diabetes escalates with increasing life expectancy, the number of older 
people with insulin-treated diabetes will increase [Whiting et al. 2011]. 
 
Insulin secretagogues, such as SUs, are effective glucose-lowering agents [Inzucchi 2002] but 
their long-term effectiveness has been questioned since they depend on a residual β-cell function 
for mechanism of action [DeFronzo 1999] and there is a strong association between glycaemic 
deterioration and progressive β-cell failure in type 2 diabetes. 
 
The main focus of these studies was issues related to the use of sulphonylureas in the treatment of 
patients with diagnosed type 2 diabetes of more than 5-10 years' duration. 
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BACKGROUND 
 
 
A PROGRESSIVE DISEASE 
The UKPDS showed that the deterioration in glycaemic control observed over time in patients 
with newly-diagnosed type 2 diabetes is associated with a decrease in β-cell function [UKPDS 
1995]. Other long-term follow-up studies reported a decrease in insulin secretion over time 
[Niskanen et al. 1994; Levy et al. 1998] and in cross-sectional studies lower insulin secretion has 
been associated with longer diabetes duration [Clauson et al. 1994; Shim et al. 2006; Funakoshi et 
al. 2008]. However, chronic hyperglycaemia itself contributes to impaired insulin secretion by 
making the β-cell unresponsive to glucose – the glucotoxicity effect [Leahy et al. 1992]. This may 
affect the observed decrease in insulin secretion, since glycaemic control deteriorated with time as 
shown in those studies.  
 
Although it seems clear that β-cell function declines over time in patients with type 2 diabetes as a 
group, the disease is probably heterogeneous with respect to decreasing β -cell function, and the 
loss of insulin secretory capacity may not be inexorable [Zangeneh et al. 2006]. Two long-term 
follow-up studies have, in contrast to others, reported that insulin secretory capacity can be 
preserved for up to twenty years in some patients [Zangeneh et al. 2006; Ekholm et al. 2012]. 
Notably, in these studies glycaemic control improved as a result of more intensive treatments. 
 
In an analysis from the UKPDS assessing the number of patients attaining glycaemic goals on 
monotherapy after nine years, only approximately 25% did so, and the conclusion was that the 
majority of patients need multiple therapies with both oral agents and insulin to attain glycaemic 
targets in the long run [Turner et al. 1999]. Using multiple therapies it is possible to minimize the 
progressive deterioration in HbA1c as was shown in the Action in Diabetes and Vascular Disease: 
Preterax- and Diamicron-modified Controlled Evaluation study (ADVANCE), in which HbA1c 
decreased over five years [Patel et al. 2008]. 
 
Longitudinal data regarding glucose-lowering treatments and glycaemic control in patients with 
type 2 diabetes from the U.S. National Health and Nutrition Examination Survey (NHANES, 
1988-2000 and 1999-2004) show that treatment regimens have changed substantially over fifteen 
years, with a marked increase of combined oral glucose-lowering agents and insulin [Koro et al. 
2004; Ong et al. 2008]. With this combined therapy, glycaemic control improved between 1999 
and 2004, and HbA1c decreased from 7.9% to 7.2% (IFCC 63-55 mmol/mol) and 52% of patients 
had an HbA1c < 7.0% (53 mmol/mol) [Ong et al. 2008]. 
 
β-cell failure 
 
The pathogenesis of type 2 diabetes is complex, involving both genetic and environmental factors. 
In a non-diabetic person β-cells can balance changes in insulin sensitivity with proportionate 
changes in insulin secretion, thus keeping blood glucose at normal levels [Kahn et al. 1993]. In a 
person with type 2 diabetes a combination of reduced β-cell mass and decreased function together 
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with insulin resistance results in β-cells incapable of compensating adequately for increased 
secretory demand due to insulin resistance [Lyssenko et al. 2005; Karaca et al. 2009]. When the 
β-cell compensation becomes insufficient, early in the course of the disease, a mild increase in 
glycaemia occurs when moving from normal to impaired glucose tolerance, progressing to overt 
diabetes [Leahy et al. 2010], see figure 1. 
 
 
 Figure 1. Key pathological features of type 2 diabetes. 
 Adapted with permission from J.L. Leahy; Arch Med Res 36:197-209, 2005. 
 
The initial increase in glycaemia causes further deterioration in β-cell function through a number 
of proposed mechanisms such as gluco- and lipotoxicity. These contribute to the progressive im-
pairment of insulin secretion and lower insulin sensitivity while hyperglycaemia progresses 
[Unger 1995; Poitout et al. 2002]. Other acquired factors that may contribute to β-cell failure or 
death are increased deposition of islet amyloid polypeptide (IAPP) [Butler et al. 2003] and 
inflammatory cytokines [Donath et al. 2005]. In combination, all these factors interact on the β-
cell, leading to decreased function and lowered mass. Besides the β-cell defects there are various 
degrees of insulin resistance early in the course of the disease; but it is the worsening of β-cell 
function and insulin secretion that is believed to be responsible for the progressive rise in 
glycaemia [Weyer et al. 1999]. 
 
Methods for evaluating insulin secretion and β-cell function 
 
The homeostasis model assessment, HOMA [Matthews et al. 1985], is the best known and 
validated method [Hermans et al. 1999] for assessing insulin secretion. The HOMA-B estimates 
β-cell function with a mathematical formula involving fasting plasma insulin (or C-peptide), and 
glucose concentrations. The original formula can be written: 
 
 
In 2004 a HOMA calculator was released online which provides model-derived estimates rather 
than linear approximations. As insulin is part of the formula, the model cannot be used in patients 
HOMA-B =   
20 x fasting P-insulin (µU/ml) 
FPG (mmol/L) -3.5 
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taking exogenous insulin. It does not provide information on the dynamic relationship between 
insulin sensitivity and secretion.  
An oral glucose tolerance test (OGTT) is easy to perform and, besides its use for diagnosing 
impaired glucose tolerance or diabetes, it can be used to assess β-cell function. The measure most 
commonly examined, after 75 g oral glucose load, is the early insulin response, the insulinogenic 
index, which is determined as the ratio of the incremental insulin (or C-peptide) to glucose 
(Δinsulin/Δglucose) at 30 min [Haffner et al. 1995]. This can be followed by frequent sampling 
for up to two hours [Kahn et al. 2008]. Instead of oral glucose a meal tolerance test with frequent 
sampling can be performed [Mari et al. 2002]. 
 
 
 Figure 2. Human proinsulin. B-chain (dark blue) and A-chain (light blue) are 
                  linked by C-peptide (orange). 
 
C-peptide is co-secreted by the pancreas in an equimolar ratio with insulin and has been used as a 
tool for assessing insulin secretion (Fig. 2). Unlike insulin, C-peptide is not cleared by the liver, 
making it a more suitable peptide for assessing endogenous insulin secretion than insulin 
[Hovorka et al. 1998]. Measuring C-peptide after stimulation with intravenous glucagon provides 
a reliable estimate of β-cell function [Gjessing et al. 1987] and has been widely used. Another 
option is the standard breakfast test since there is a good correlation between C-peptide incre-
ments in these two tests [Koskinen et al. 1988; Escobar-Jimenez et al. 1990]. 
 
Indexes for evaluation of fasting and postprandial β-cell responsiveness by using C-peptide after a 
standard meal have been developed [Hovorka et al. 1998]. Fasting β-cell responsiveness is the 
ratio of fasting C-peptide/glucose. Postprandial β-cell responsiveness represents the ability of 
postprandial glucose to stimulate C-peptide secretion. It corresponds to the increment in 
postprandial C-peptide divided by the increment in postprandial glucose (ΔC-peptide/Δglucose).  
 
In addition to the tests described above, various experimental methods for measuring insulin 
secretion and insulin sensitivity have been developed. The gold standard is the glucose clamp 
technique, originally described by DeFronzo et al [DeFronzo et al. 1979]. This can be done as a 
hyperglycaemic clamp when the plasma glucose level is raised by intravenous glucose infusion 
and held constant. During the constant hyperglycaemia, insulin secretory response is measured. 
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Another option is the euglycaemic insulin clamp, when insulin is infused at a constant rate and the 
amount of glucose infused to maintain glucose at a constant level serves as a measure of insulin 
sensitivity. A further test used in experimental settings is the intravenous glucose tolerance test 
(IVGTT), in which the acute insulin response 30 minutes after a glucose bolus injection is 
measured and then followed by frequent sampling for up to 4 hours [Brunzell et al. 1976]. 
 
While the intravenous tests provide detailed information on the dynamic state of the relationship 
between insulin secretion and sensitivity, they are far too complicated to be used in a clinical 
setting or in larger clinical studies. A review article from 2004 concluded that there is no single 
test that allows β-cell function to be assessed with accuracy and specificity because of the 
enormous complexity of β-cell behaviour in vivo [Ferrannini et al. 2004]. Generally, since there is 
no consensus on a reference method, the results from various tests should be interpreted in the 
context of actual glucose levels and insulin sensitivity, especially when using more simple tests. 
 
 
GLYCAEMIC GOALS 
 
Data from recent intervention studies in type 2 diabetes [Gerstein et al. 2008; Patel et al. 2008; 
Duckworth et al. 2009] suggested that not everyone benefits from intensive glucose management. 
This has resulted in a re-examination of the rigorous glycaemic targets for all patients, and the 
benefit of an intensified glucose control has been questioned [Yudkin et al. 2010]. 
 
In 2012 the American Diabetes Association (ADA) and the European Association for the Study of 
Diabetes (EASD) published a position statement emphasizing the importance of a patient-centred 
approach to the management of hyperglycaemia [Inzucchi et al. 2012]. According to this 
document glycaemic targets in type 2 diabetes should be individualized depending on age, 
diabetes duration, presence of diabetes complications and propensity for hypoglycaemia. Further, 
the patient’s capacity for self-care, living conditions, cognitive status and overall prognosis should 
be taken into consideration. Finally, glycaemic targets should be flexible, adapted to changes in 
the patient’s health conditions; and the patient should be an active participant in setting goals 
[Ismail-Beigi et al. 2011]. 
 
Glycosylated haemoglobin, HbA1c, is a measurement that reflects the average plasma glucose 
concentration over a period of up to12 weeks. It is used for setting glycaemic goals and evaluating 
glycaemic control. There has been no standardized method for measuring HbA1c but the most 
common world-wide has been the DCCT aligned assays. These are managed through the National 
Glycohaemoglobin Standardization Program, NGSP, [Little et al. 2011] with a reference value 
≤ 6.0%. In Sweden HbA1c has been measured with the Mono-S method with a reference value of 
≤ 5.2%. The NGSP/DCCT standard is approximately 0.9% higher than the Mono-S. In 2010 a 
new worldwide general standard for HbA1c was agreed upon by major diabetes organizations 
[Hanås et al. 2010] after recommendations from a working group in the International Federation 
of Clinical Chemistry and Laboratory Medicine (IFCC). HbA1c results are now to be reported in 
IFCC units (mmol/mol) and derived NGSP units (%) [IFCC 2007]. 
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In Swedish guidelines for the management of diabetes from the National Board of Health and 
Welfare [Socialstyrelsen 2010] the recommended overall treatment goal is an HbA1c level of < 52 
mmol/mol, (< 6.0% Mono-S or < 6.9% NGSP). However, the guidelines state that risks versus 
benefits for each patient should be assessed to individualize the glycaemic goal. 
 
 
PHARMACOLOGICAL TREATMENT 
 
Lifestyle intervention is the basis for treatment of type 2 diabetes, but pharmacological treatment 
of hyperglycaemia is needed in almost all patients sooner or later due to the progressive nature of 
the disease. Figure 3 gives an overview of all classes of oral glucose-lowering drugs available on 
the market in August 2012. 
 
 
Figure 3. Pharmacological treatment of type 2 diabetes according to site of action.  
 Published with permission from Stumvoll et al. Type 2 diabetes: principles of 
 pathogenesis and therapy. Lancet 2005. 365: p. 1333-46. 
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Metformin is considered in most guidelines to be the first choice of oral glucose-lowering 
medication [IDF 2006; Home et al. 2008; Nathan et al. 2009; Inzucchi et al. 2012]. However, 
what to add after metformin when glycaemic control deteriorates is more difficult to agree upon, 
mainly because of a lack of good clinical comparison studies of different drugs [Bennett et al. 
2011]. Some guidelines recommend SU as second-line treatment after metformin [IDF 2006; 
Home et al. 2008]. In general, the addition of a second oral drug is, on average, associated with a 
reduction of HbA1c of approximately 1% i.e. IFCC 11 mmol/mol [Bennett et al. 2011]. Insulin is 
the most effective drug for lowering glucose and should be added relatively early, e.g. if HbA1c 
rises ≥ 7.5% (NGSP; IFCC > 58 mmol/mol) [IDF 2006; Home et al.2008]. Insulin can, when used 
in adequate doses, decrease any level of elevated HbA1c to, or close to, the therapeutic goal 
[Nathan et al. 2009].  
 
The evidence basis for how to combine different glucose-lowering agents, and in what order they 
should be added, is lean. Data from clinical studies shows median responses and does not address 
the important question of who responds to which therapy and why [Smith et al. 2010]. The 
uncertainties in terms of which drug to choose, how to combine and when, for treatment of type 2 
diabetes have resulted in a more patient-centred care [Glasgow et al. 2008]. Consequently, in the 
recent position statement from ADA/EASD on the management of hyperglycaemia the 
recommendations are “less prescriptive and not as algorithmic as prior guidelines”, manifested in 
suggestions such as the following: if the HbA1c target is not achieved in three months, add either a 
second oral agent, a GLP-1 receptor agonist or insulin; the choice should be based on patient- and 
drug-specific characteristics with the primary goal to improve glycaemic control while mini-
mizing side effects [Inzucchi et al. 2012]. Individualization is thus the cornerstone of success and 
the advantages and disadvantages of specific drugs for each patient should be considered when 
seeking the optimal therapy for a given patient [Inzucchi et al. 2012]. 
 
Since type 2 diabetes affects so many people, costs are a critical issue when choosing glucose-
lowering therapy. Access to many of the options for treatment is limited in many middle- and 
low-income countries and less expensive agents are to be used [Colagiuri 2012]. 
 
Sulphonylureas 
 
Sulphonylureas have been used for treating type 2 diabetes since the mid-1950s. These drugs 
enhance insulin secretion [Gotfredsen 1976] by binding to a SU receptor on the surface of the β-
cell. This leads to a closure of potassium adenosine triphosphate (KATP) channels followed by an 
opening of calcium channels, which in turn triggers insulin secretion [Zimmerman 1997]. These 
ATP-sensitive potassium channels are also found in the myocardium, in skeletal and smooth 
muscle [Ashcroft et al. 1992]. The clinically most important adverse effects of SUs are hypo-
glycaemia and weight gain [UKPDS 1998; Inzucchi 2002].  
 
The currently available SU compounds glibenclamide (glyburide in the U.S.), glipizide, gliclazide 
(not available for prescription in Sweden) and glimepiride are associated with similar reductions 
in HbA1c levels of 1-1.5 % i.e. IFCC 11-16 mmol/mol [Clark et al. 1998; Sherifali et al. 2010]. 
Despite their similar glucose-lowering efficacy there are some clinically important differences 
between the various SUs. Thus gliclazide, glipizide and glimepiride have less adverse effects than 
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glibenclamide and hypoglycaemia frequency is clearly highest with glibenclamide [Rendell 2004] 
while gliclazide and glimepiride have a lower frequency, reportedly the same for both compounds 
[Tsumura 1995]. 
 
Glibenclamide has long been the most used SU compound worldwide, but its continued use has 
been questioned because of the safety concerns linked to this drug compared to the other SUs 
[Riddle 2010]. One major concern is that glibenclamide is associated with a greater risk of hypo-
glycaemia than the other SUs are [van Staa et al. 1997] and hence glibenclamide is no longer 
subsidized in Sweden for new patients as decided by the Dental and Pharmaceutical Benefits 
Agency [TLV 2010]. Another concern is related to a possible deleterious effect on cardiovascular 
events because of a negative effect of glibenclamide on what is termed myocardial ischemic 
preconditioning [Engler et al. 1996; Leibowitz et al. 1996].  
 
Observational studies, mostly retrospective, of mortality and cardiovascular risk associated with 
the use of SU have reported conflicting results [Schramm et al. 2011; Pantalone et al. 2012]. In 
studies suggesting a poorer outcome with SU therapy, glibenclamide was the most commonly 
used SU, but the results were assumed to be the same for all different SUs [Evans et al. 2006; 
Simpson et al. 2006]. A recent, prospective, study aiming to determine whether SUs in general, 
and glibenclamide in particular, alter the risk of death or other in-hospital outcomes in patients 
with acute myocardial infarction, showed no increased mortality risk in patients on chronic SU 
therapy [Zeller et al. 2010] However, the risk of early mortality was significantly lower with 
glimepiride or gliclazide than with glibenclamide. The result is consistent with the findings that 
the newer classes of SUs do not interact with KATP channels in the heart. When gliclazide-based 
therapy was used in the large, prospective, ADVANCE study, there was a significant reduction in 
microvascular events in the intensively-treated group and this was achieved with a low frequency 
of hypoglycaemia and no increase in CVD mortality [Patel et al. 2008]. 
 
Glimepiride was introduced 1996 as the most recent SU compound on the market. It is one of the 
recommended SUs in Sweden along with glipizide [Läkemedelsverket 2010]. Glimepiride has 
pharmacological properties that may be advantageous when compared to other SUs [Korytkowski 
2004]. It is associated with lower rates of hypoglycaemia than glibenclamide [Dills et al. 1996; 
Holstein et al. 2001]. This could be because it has a lower binding affinity for the β-cell SU 
receptor [Kramer et al. 1996] and because lower levels of insulin and C-peptide are produced by 
glimepiride at the same level of glycaemia [Raptis et al. 1999]. The avoidance of excess insulin 
concentrations with glimepiride could also play a role for the weight neutrality or even weight 
loss that has been associated with glimepiride therapy [Bugos et al. 2000; Scholz et al. 2001; 
Weitgasser et al. 2003]. Glimepiride is quite exclusively specific to the pancreatic β-cells and 
reportedly does not induce negative effects on ischemic preconditioning in experimental myo-
cardial ischemia [Klepzig et al. 1999]. The elimination of glimepiride in patients with renal 
impairment is not changed, making it a safer option in these patients [Rosenkranz et al. 1996]. 
 
The fact that SUs lose their efficacy over time or, more precisely, that there is a successive need 
for multiple therapies due to declining β-cell function has raised the concern that SU may exhaust 
β-cell function. This opinion emerges from studies indicating that glibenclamide can accelerate β-
cell apoptosis in human β-cell islets [Maedler et al. 2005]. Other mechanisms proposing that SU 
may be deleterious for β-cells are that islet amyloidosis observed in patients with type 2 diabetes 
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is related to the degree of β-cell impairment in humans [Westermark et al. 2011]. Amyloidosis is 
formed primarily by deposition of islet amyloid polypeptide (IAPP) which, has been proposed, to 
be involved in the development of β-cell dysfunction [Clark et al. 1996]. There is experimental 
evidence for an association between elevated IAPP secretion, SU treatment and islet amyloidosis 
[Hoenig et al. 2000]. A third hypothesis, put forward in one clinical study [Pfutzner et al. 2006], is 
that an increased secretion of proinsulin, which is viewed as a symptom of a stressed β-cell 
[Hostens et al. 1999], is associated with SU therapy.  
In the Diabetes Outcome Progression Study (ADOPT) [Kahn et al. 2006] glycaemic durability 
and changes in β-cell function were studied over four years in patients allocated to rosiglitazone, 
metformin or glyburide. The study showed a more rapid decline in insulin secretion and 
glycaemic control with glyburide, and the authors conclude that it was the more rapid loss of β-
cell function with glyburide that led to the increasing FPG and HbA1c in patients allocated to this 
drug. 
 
Why SU and insulin?  
 
Adding SU to metformin, the first drug of choice in the treatment of type 2 diabetes, is one of the 
options when glycaemic control deteriorates and a second drug is needed [Inzucchi et al. 2012]. 
However, the benefits of combining an insulin secretagogue, such as SU, with exogenous insulin 
are not as obvious [Raskin 2008]. 
 
The idea of combining insulin and SU originally came from early reports suggesting that SUs 
were thought to have extra-pancreatic effects leading to increased peripheral and hepatic insulin 
sensitivity [Melander et al. 1990] – in addition to stimulating endogenous insulin secretion. 
However, in vivo studies have not confirmed such effects of SUs [Gutniak et al. 1987] and their 
proposed peripheral effects are most likely secondary to a reduction in glucotoxicity. In the mid- 
1980s, when metformin was not available in the US, combining SU with bedtime insulin was a 
therapy regimen introduced [Riddle et al. 1984]. In the 1990s three meta-analyses of combined 
SU and insulin therapy were published [Peters et al. 1991; Pugh et al. 1992; Johnson et al. 1996]. 
They concluded that, compared to insulin monotherapy, combination therapy improved glycaemic 
control with fewer exogenous insulin doses. Many investigators have documented the efficacy of 
insulin and SU therapy, showing better HbA1c with combination therapy [Shank et al. 1995; 
Feinglos et al. 1998; Janka et al. 2007; Ebato et al. 2009]. 
 
One advantage of combining SU and insulin is that the insulin doses often can be reduced. In a 
review [Yki-Järvinen 2001] of 22 studies comparing combination therapy with insulin mono-
therapy, the insulin dose was, in mean, 42% lower with combination SU and insulin. The insulin-
sparing effect of SU in combination therapy was also the conclusion from the earlier meta-
analyses [Peters et al. 1991; Pugh et al. 1992; Johnson et al. 1996]. Another possible advantage is 
that the increase in body weight associated with improved glycaemic control [Mäkimattila et al. 
1999] may be somewhat smaller with combined insulin and SU than with insulin monotherapy for 
the same level of glycaemia [Chow et al. 1995; Landstedt-Hallin et al. 1995; Clauson et al. 1996; 
Riddle et al. 1998; Yki-Järvinen et al. 1999]. A possible disadvantage of combining an insulin 
secretagogue with insulin could theoretically be an increased risk of hypoglycaemia. However, 
studies have suggested that combination therapy is accompanied by a similar [Yki-Järvinen 2001] 
or lower [Kabadi et al. 2003; Goudswaard et al. 2004; Janka et al. 2005] frequency of hypo-
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glycaemia. One explanation could be the insulin-sparing effect of SUs since endogenous insulin 
probably has physiological benefits compared to exogenous insulin [Lebovitz 2011]; and when 
more of the glycaemic control is achieved with endogenous insulin, glycaemic stability may 
improve [Riddle et al. 1992]. 
 
As SUs stimulate insulin secretion they depend on residual β-cell function and, given the 
progressive nature of type 2 diabetes, they would be expected to be less effective over time; but 
few studies evaluate the long-term efficacy of combined SU + insulin therapy. In the ADVANCE 
study patients in the intensive treatment group, in which approximately 50% were on combined 
gliclazide + insulin therapy, achieved HbA1c of 6.5% (NSGP; Mono-S 5.6%, IFCC 48 mmol/mol) 
after a median follow-up of five years. A sub-study of the UKPDS [Wright et al. 2002], which 
used a modified protocol for the last UKPDS centres, allowed the addition of insulin in patients 
allocated to SU if maximal doses of SU did not maintain FPG < 6.0 mmol/l. After six years 52% 
of patients required combination therapy, and SU + insulin resulted in a lower HbA1c than in the 
insulin monotherapy group. A clinically important question is clearly whether SU remain 
effective in patients with long diabetes duration. 
 
 
HYPOGLYCAEMIA IN TYPE 2 DIABETES 
 
There is no consensus on a common definition of biochemical hypoglycaemia [Service 1995] and 
thus definitions based on symptomatology have been adopted. Mild hypoglycaemia is defined as 
an event where symptoms suggestive of hypoglycaemia are successfully treated by the patient 
alone, while episodes requiring third-party assistance are defined as severe [Zammitt et al. 2005]. 
 
Symptoms of hypoglycaemia are usually classified as autonomic, neuroglycopenic and non-
specific. Elderly people report a profile of hypoglycaemic symptoms that partly differs from that 
of young adults, and the intensity of their symptoms is less [Brierley et al. 1995]. In young adults, 
symptoms of hypoglycaemia are generated at a glucose level that is around 1 mmol/l higher than 
the level at which cognitive function becomes impaired [Schwartz et al. 1987], while in elderly 
subjects these thresholds are much closer together, allowing less time for remedial action [Matyka 
et al. 1997]. Moreover, in elderly diabetes patients, neurological symptoms affecting vision and 
co-ordination have been identified as more frequent and may be confused with other conditions 
such as a transient ischemic attack or a vasovagal episode [Jaap et al. 1998; McAulay et al. 2001]. 
The risk that a hypoglycaemic episode is not correctly identified and treated in elderly type 2 
patients is also magnified by the fact that many of these patients and their relatives have limited 
knowledge of hypoglycaemic symptoms [Mutch et al. 1985; Pegg et al. 1991]. Notably, a recent 
UK prospective survey documented that while only 10% of episodes of severe hypoglycaemia 
affecting type 1 patients required the assistance of emergency medical services, one in three of 
type 2 patients affected needed to enlist help from such services [Donnelly et al. 2005]. Impaired 
awareness of hypoglycaemia, which is a prominent risk factor for severe hypoglycaemia in type 1 
diabetes, [Bragd et al. 2003] is less common in type 2 diabetes, affecting only 8 % according to 
one retrospective survey in insulin-treated type 2 patients [Henderson et al. 2003]. 
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Most studies concerning the frequency of hypoglycaemia in type 2 diabetes patients have been 
conducted retrospectively and the definitions of hypoglycaemia and the nature of the treatment 
modalities examined both differ between studies thus hindering comparison [Zammitt et al. 2005]. 
Reported prevalence figures concerning severe hypoglycaemia in type 2 diabetes range from 
2.3% [UKPDS 1998] to 16.5% in insulin-treated patients as revealed by a retrospective question-
naire [Akram et al. 2006]. The prevalence of severe hypoglycaemia in patients with type 2 
diabetes appears to increase with duration of insulin therapy [Henderson et al. 2003], and this is in 
line with what is well-known amongst patients with type 1 diabetes [Bragd et al. 2003]. 
 
 
CONTINUOUS GLUCOSE MONITORING 
 
The first continuous glucose monitoring product, the CGMS® System, was introduced for 
monitoring glucose in 2000 by Medtronic Minimed. CGMS is a Holter-type sensor system that 
continuously measures interstitial glucose levels, usually in subcutaneous tissue of the abdomen. 
The sensor is a microelectrode that generates an electrical signal of which the strength is 
proportional to the glucose concentration in the fluid. The system generates a value every 5 
minutes, 288 readings per day, measuring glucose levels between 2.2 and 22.2 mmol/l. It has to 
be calibrated with capillary plasma glucose 3-4 times every 24 hours. In the second-generation 
CGMS GoldTM, launched in 2003, like in the initial CGMS, the current glucose values are not 
shown for the person being monitored and the system can only be used for retrospective analysis. 
The newer CGMS systems monitor interstitial glucose in real time and are most commonly used 
in clinical practice. 
The advantages of CGMS are that it provides more data on glycaemic excursions than obtainable 
by self-monitoring of plasma glucose (SMPG) and that it gives the opportunity to monitor 
nocturnal profiles of glucose. The system was initially used for detecting unrecognized nocturnal 
hypoglycaemias in type 1 patients [Boland et al. 2001; Chase et al. 2001]. Although CGMS has 
been used less in patients with type 2 diabetes, studies suggest a high frequency of hypoglycaemic 
episodes, mostly unrecognized, during nighttime. The conclusion from these studies has generally 
been that CGMS is a useful tool to assess nocturnal glycaemia [Hay et al. 2003; Zick et al. 2007]. 
CGMS may be a valuable tool for improving glycaemic control [Klonoff 2005] and avoiding 
hypoglycaemia [Garg et al. 2006]. To provide clinical benefits it is important that sensor readings 
adequately reflect actual plasma glucose and for this reason sensor accuracy is important. The 
agreement between sensor readings and meter values (calibration values) has been acceptable in 
several studies [Gross et al. 2000; Sachedina et al. 2003; Kubiak et al. 2004]. 
It was suspected that the first generation CGMS overread nocturnal hypoglycaemia because of a 
high incidence of asymptomatic low glucose values [Klonoff 2005]. A study from 2002 reported 
spurious hypoglycaemic readings during nighttime when compared to simultaneously measured 
glucose reference values [McGowan et al. 2002]. 
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AIMS 
 
 
§ to assess the effect of sulphonylureas (SU) in patients on SU + insulin therapy by 
withdrawal of SU, and to identify clinically useful markers of long-term response 
(Study I) 
 
§ to describe long-term changes in glycaemic control and β-cell function, assessed as 
postprandial C-peptide and C-peptide/glucose ratio, in relation to treatment with 
SU over a period of 10 years (Study II) 
 
§ to assess the effect of SU in patients on metformin + insulin therapy – assessed as 
HbA1c and by CGMS – by adding glimepiride, and to identify predictors of long-
term responsiveness to SU (Study III) 
 
§ to study the accuracy of continuous nocturnal glucose monitoring (CGMS) in 
patients with type 2 diabetes on combined oral and insulin therapy (Study IV) 
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PATIENTS AND METHODS 
 
OVERVIEW 
Study characteristics 
All participants were recruited either from the Diabetes Day Care Centre at Danderyd University 
Hospital, or through contacts with primary care physicians in the Stockholm area or through 
newspaper advertisements. Table 1 summarizes the characteristics of the studies while Table 2 
summarizes the inclusion criteria for Studies I+III.  
 
Table 1. Summary of study characteristics 
 
 Number 
of subjects 
Study 
performed Study design Outcome 
Study I 25 2003–2005 Open, prospective, observational Fasting P-glucose, HbA1c  
Study II 171 2006–2007 Observational 
Ratio postprandial C-peptide/ 
glucose and HbA1c related to 
use of SU 
Study III 43 2010-2012 
Randomized, 
placebo-controlled, 
prospective, cross-over 
HbA1c 
Insulin doses 
Frequency of hypoglycaemia 
Study IV 14 1999-2003 Prospective, pilot Correlation between CGMS readings and venous P-glucose 
 
 
Table 2. Inclusion criteria for Studies I and III 
 
 Study I Study III 
Age No limitations 40-75 
Diabetes 
duration 
≥ 5 years with combined SU + 
insulin± metformin 
≥ 10 years treatment with metformin + 
insulin ≥ 1 year prior to inclusion 
HbA1c < 8.5% (IFCC < 78 mmol/mol) 6-8.5% (IFCC 52-78 mmol/mol) 
BMI No limitations 24-40 kg/m2 
SU-treatment ≥ 5 years no SU during the past year 
Other - Fasting C-peptide/glucose ratio ≥ 0.045* 
* The cut-off value for fasting ratio C-peptide/glucose ≥ 0.045 as an inclusion criterion was based 
on data from Study II, in which the lower quartile of fasting ratio C-peptide/glucose in patients 
treated with metformin and insulin was 0.045.  
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Exclusion criteria in Studies I and III 
Study I: intercurrent infection or other disease that could affect metabolic control; proliferative 
retinopathy as assessed by an eye exam within the previous 12 months; inability to perform self 
monitoring of plasma glucose (SMPG). 
 
Study III: intercurrent diseases of major importance e.g. severe heart disease; renal insufficiency 
(serum creatinine > 130 µmol/l); liver transaminases three times the normal value, untreated 
proliferative retinopathy; inability to perform SMPG; SU treatment during the previous year.  
 
 
Patient characteristics 
Patient characteristics at baseline (Studies I, III, IV) or at follow-up (Study II) are summarized 
below. 
 
Table 3. Summary of patient characteristics. Data are given as median and range. 
 
 Study I Study II Study III Study IV 
Number of patients 25 171 43 14 
Sex (% women) 20%  38% 42% 43% 
Age (years) 67 (59-83) 68 (40-87) 66 (46-74) 60 (53-69) 
Diabetes duration (years) 19 (8-29) 14 (8-46) 16 (10-30) 10 (3-29) 
SU therapy (years) 15 (7-24) n/a n/a 10 (1-29) 
Insulin therapy (years) 10 (6-15) n/a n/a 5 (1-14) 
BMI (kg/m2) 30 (23-44) 30 (20-46) 30 (25-37) 28 (24-33) 
Insulin dose (U/kg) 0.50 (0.29-1.06) - 0.50 (0.09-2.68) 0.52 (0.11-1.46) 
Fasting P-glucose 
(mmol/l) 8.5 (4.7-13.7 8.4 (2.3-20) 8.7 (3.6-16.7) 9.1 (4-20.6) 
HbA1c  
(Mono-S, %) 7.0 (5.8-8.3) 6.7 (4.5-13) 7.2 (5.9-8.3) 6.9 (5.7-8.4) 
HbA1c  
(IFCC, mmol/mol) 63 (50-76) 59 (36-125) 65 (51-76) 61 (49-77) 
Fasting C-peptide 
(nmol/l) 
0.67 
(0.26-1.80) 
0.70 
(0.04-3.2) 
0.69 
(0.09-2.1) 
0.58 
(0.28-0.94) 
Ratio fasting  
C-peptide/glucose 
0.083 
(0.021-0.300) 
0.082 
(0.003-0.457) 
0.084 
(0.025-0.233) 
0.075 
(0.023-0.250) 
Postprandial  
C-peptide (nmol/l) 
1.70 
(0.72-3.30) 
1.4 
(0.04-3.8) 
1.50 
(0.30-2.70) n/a 
Ratio postprandial  
C-peptide/glucose 
0.108 
(0.038-0.265) 
0.128 
(0.004-0.561) 
0.125 
(0.036-0.237) n/a 
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Depending on study protocol and inclusion criteria, patients included in the studies had different 
glucose-lowering therapies as summarized in Table 4. Only a few patients were on short-acting 
insulin secretagogues (glinides/meglitinides) and they are therefore presented together with SU.  
In Study I all patients, by protocol, were treated with an SU compound (76% on glibenclamide, 
16% on glimepiride, 8% on glipizide). 
 
 
Table 4: Glucose-lowering therapy. Percentage of patients on different treatments. 
 
 Study I 
(baseline) 
Study II  
(baseline) 
Study II  
(at follow-up) 
Study III 
(baseline) 
Diet only - 17 % 4 % - 
Metformin 60 % 37 % 55 % 100 % 
SU/glinides 100 % 56 % 48 % 0 % 
Acarbose/TZD - 7 % 2 % - 
Insulin 100 % 33 % 74% 100 % 
 
 
In Study I and Study III patients were on various insulin regimens at baseline (Table 5) and these 
were not changed during the studies. The insulin regimens in Study II were not recorded.  
 
 
Table 5: Percentage of patients on different insulin regimens. 
 
 Study I Study III 
Once-daily regimens 
     Bedtime NPH or glargine  
 
8 % 
 
23 % 
B.i.d. regimens 
     Morning premixed + dinner premixed  
     Morning premixed + bedtime NPH 
     Morning + bedtime NPH/glargine/detemir 
 
32 % 
12 % 
32 % 
 
23 % 
 7 % 
 7 % 
3-5 dose regimens  
     Morning, lunch and dinner premixed 
     Morning + dinner premixed  + pre-lunch analogue 
     Pre-meal analogue + bedtime NPH/glargine/detemir 
 
4 % 
4 % 
8 % 
 
- 
- 
40 % 
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STUDY AIMS AND PROTOCOLS 
Study I 
Aims: The aim of Study I was to assess the effect of SU in patients on long-term therapy with 
insulin + SU ± metformin by withdrawal of SU, and to identify clinically useful markers of long-
term response. 
Study protocol: At study start FPG, C-peptide and HbA1c were measured. Postprandial values for 
glucose and C-peptide were drawn after a standard breakfast. Before SU withdrawal FPG was 
rechecked at visit 2, and the mean value of FPG was defined as the patient’s reference glucose 
value. After visit two the patients stopped their SU medication but continued all other treatments. 
No insulin dose adjustments were allowed. After SU withdrawal FPG and C-peptide were 
measured every 2-3 days and after two weeks HbA1c was repeated. 
Patients performed SMPG daily. At two weeks SU was restarted if FPG exceeded the reference 
value ≥ 40% or if P-glucose during daytime was > 20 mmol/l. Patients whose glucose values did 
not increase according to these criteria continued without SU medication. Since 19 of 25 patients 
were on glibenclamide, whose glucose-lowering effect may be long-lasting [Jonsson et al. 2001], 
the patients whose glucose values did not increase according to the above criteria were scheduled 
for a follow-up visit within 8 weeks when HbA1c was measured. If patients’ SMPG values 
indicated worsened glycaemic control during this time, an earlier follow-up visit was scheduled. 
At the follow-up, glycaemic control was evaluated with SMPG and HbA1c, and SU was restarted 
if glycaemic control was assessed as impaired. 
 
Study II 
Aims: The aim of Study II was to describe long-term changes in glycaemic control and β-cell 
function assessed as postprandial C-peptide and C-peptide/glucose ratio, in relation to treatment 
with SU over 10 years. 
Study protocol and patients: In 1997/1998, 462 patients with type 2 diabetes attended four-day 
diabetes courses at the Diabetes Day Care Centre. Reasons for attending the course are shown in 
figure 4. Approximately ten years later all patients were invited to a follow-up visit at which point 
26% of the original group had died (Fig. 4). 
 
Figure 4. Patient flow in Study II. 
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HbA1c, postprandial values of C-peptide and P-glucose were measured at baseline 1997/98. These 
measurements were repeated at follow-up, with the addition of fasting values of C-peptide and 
glucose and GAD antibodies. The participants filled in a questionnaire about their medical history 
and current diabetes treatment and, if needed, their medical records were obtained from their 
primary health care physician to confirm on-going and/or earlier diabetes treatment.  
 
There were no differences in patient characteristics at baseline between the 171 patients that 
participated and the 170 non-participants. To further characterize the non-participants, recent 
HbA1c values and weight were obtained from 105 patients and, again, no differences were found 
between the groups. Glucose-lowering therapy at baseline and follow-up are shown in Table 4 
and figure 8. Of the patients treated with oral glucose-lowering drugs in 1997/98, 56% were on a 
SU compound and in 2007 42% were on SU (6% were on meglitinides). Combined therapy with 
oral glucose-lowering drugs and insulin increased from 18% to 52%. 
 
Study III 
Aims: The aim of Study III was to investigate the effect of SU in patients on metformin + insulin 
therapy – assessed as HbA1c and by CGMS – by adding glimepiride, and to identify predictors for 
long-term responsiveness to SU.  
Study protocol and patients: A randomized, placebo-controlled, double-blind, cross-over study 
that consisted of two treatment periods of 12 weeks each, separated by a six-week washout period 
(Fig. 5). The patients were randomly assigned to receive Amaryl® (glimepiride) followed by 
placebo or the reverse sequence, on a 1:1 basis. Glimepiride dose was up-titrated during the first 
two weeks to a dose of 4 mg. Patients continued with the same dose of metformin as before the 
study and their insulin regimen was unchanged. 
 
 
 
 
Figure 5. Design of Study III. 
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All the patients were asked to perform SMPG daily with additional measurements if symptoms of 
hypoglycaemia occurred. If fasting P-glucose was < 5.0 mmol/l or the patient had hypoglycaemia, 
insulin dose reduction was considered. Hypoglycaemia was defined as grade 1: only symptomatic 
and P-glucose > 3.1 mmol/l, grade 2 (minor): P-glucose < 3.1 mmol/l and grade 3 (major), 
requiring assistance from a third person [Holman et al. 2007]. 
 
Six visits were scheduled (Fig. 5) but during the first weeks of each treatment period, during up-
titration of the study drug, telephone contacts with a nurse were also scheduled to assess the 
patient’s SMPG and insulin doses for possible dose reduction. HbA1c, fasting P-glucose and C-
peptide were measured at start of each treatment period, after six weeks and at the end of treat-
ment. Postprandial samples for glucose and C-peptide were drawn 1.5 hours after a standardized 
breakfast at start and end of each period. During the washout period, insulin doses, if reduced 
during the first treatment phase, were readjusted so as to reset to the dose at start. 
 
During 72 hours at the end of each treatment period, glucose values were recorded with the 
MiniMed CGMS Gold™ (Medtronic, version 3.0, Northridge, CA). CGMS recordings were 
analysed according to criteria for optimal accuracy given by Medtronic. Nocturnal hypoglycaemia 
during CGMS was defined as a set of at least two consecutive measurements < 3.1 mmol/l 
between 00-06 h. Time spent at these levels was calculated. 
 
Sixty-six patients were screened. Twenty-three were not eligible, 11 because of a low fasting ratio 
C-peptide/glucose (< 0.045), 11 because of HbA1c not being between 6.0-8.5% (Mono-S) and one 
because of elevated serum creatinine. Of the 43 patients that were randomized, twenty had been 
treated with an SU compound before; however not during the previous year since this was an 
exclusion criterion, with variable duration of SU therapy from a few months up to fifteen years. 
 
 
Study IV 
Aims: Study IV aimed to examine the accuracy of nocturnal continuous glucose monitoring 
(CGMS) in patients on combined oral and insulin therapy. 
Study protocol and patients: The CGMS was inserted into subcutaneous fat tissue of the 
abdomen at least 15 cm from the insertion site of the insulin pump and calibrated according to 
Medtronic guidelines [Gross et al. 2000]. Each patient remained ambulatory, living their 
ordinary life, and sensors were calibrated using four capillary plasma glucose measurements 
between 7 AM and 10 PM. After two or three days subjects were admitted to the Clinical 
Research Centre. Patients took insulin as per their current routine. From 8 PM to 6 AM, venous 
blood was drawn seven times for immediate analysis (Fig. 6). These samples are referred to as 
“reference values” and were not used for calibration of the CGMS.  
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Figure 6. Overview of schedule for overnight sampling in Study IV. 
 
The subjects were recruited among patients referred to the Diabetes Day Care Centre due to poor 
glycaemic control and subsequently enrolled in a clinical study to improve glucose control with 
insulin given as NPH insulin b.i.d. + repaglinide (NovoNorm®) or basal insulin delivered by an 
insulin pump (H-TronV100®) to supply a basal dose of Humalog insulin. All patients received 
metformin and a fixed pre-meal dose of repaglinide of 4 mg three times daily. 
 
 
 
LABORATORY ANALYSES 
Plasma glucose was analysed with a glucose oxidase method (Beckman instruments) in Studies 
I-III. In Study IV plasma glucose was analysed with Precision Plus, Medisense. 
HbA1c was measured using high-performance liquid chromatography (Variant II) Mono-S with a 
normal value of less than 5.2% and a coefficient of variation (CV) of 2.6 % in Studies I and II 
and of 1.55% in Study III.  
Serum-C-peptide concentrations were measured immunologically using commercial kits: in 
Studies I and II Auto DELFIA, and in Study III Modular E, reference value 0.25-1.0 nmol/L and 
a CV of 8% and 3% respectively.  
Antibodies against Glutamic Acid Decarboxylase (GAD) were analysed by radioimmunoassay: 
Diamyd Anti-GAD65 RIA in Study I and IV and enzyme immunoassay, Medizym Medipan 
GMBH in Studies II and III – all with a negative value ≤ 5 IE/ml. 
 
 
 
STATISTICS 
The statistical analyses were performed using the STATISTICA software, version 7 in Study I 
and version 8 in Studies II and III (StatSoft® Inc., Tulsa, OK, USA). The JMP package 3.1.5 
(SAS Institute Inc., Cary, NC, USA) was used in Study IV. For Study III the statistics were 
performed by a statistician using R for Statistical Computing (version 2.14.1, Vienna, Austria) for 
the linear mixed model and regression analyses.  
 
P values < 0.05 were considered statistically significant in all the studies. 
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Study I 
After validation for normal distribution using the Shapiro-Wilk test, the Student’s t-test for paired 
continuous variables was used for comparisons between baseline and end values. The unpaired 
t-test was used for comparisons between the groups “responders” and “non-responders”. Simple 
regression analysis was used to ascertain the correlation between parameters. To evaluate factors 
related to change in FPG a stepwise linear regression was used. Factors considered were age, 
diabetes duration, HbA1c, weight, insulin dose/kg and fasting C-peptide/glucose ratio. 
 
Study II 
A simple linear regression analysis was used to evaluate the relation between postprandial C-
peptide/glucose ratio and HbA1c and diabetes duration. A multivariable regression model was 
performed to evaluate the effects on long-term change in postprandial C-peptide/glucose. The 
difference in C-peptide/glucose ratio between 1997/98 and 2007 was used as outcome (dependent 
variable). Variables used in the regression model were gender, baseline age, BMI, duration and 
baseline postprandial C-peptide/glucose ratio, change in HbA1c (classified in categories: < -0.2, 
> 0.2, and -0.2 to 0.2), GAD antibody class (≥ 200 and < 200) and SU treatment (classified as 
continuously, periodically or never). A backward selection (exclusion criterion: P > 0.05) was 
used to decide which variables to include in the final model. Baseline BMI, duration, change in 
HbA1c, SU treatment, baseline postprandial C-peptide/glucose and GAD were included regardless 
of P-value. To evaluate the effect of a single predictor on the regression, the difference in R2 
(coefficient of determination) between the final model and a reduced model was calculated. 
 
Study III  
The primary endpoint HbA1c was analysed using a linear mixed model where HbA1c at visits 2 
and 3 within each period were included as the dependent variable. Group, time, baseline HbA1c in 
each period, sequence and period were added as fixed factors, and subject was added as a random 
factor. Based on this model the difference between treatment groups can be inferred. The 
interaction between group and time was evaluated and considered non-significant. To evaluate 
factors related to a change in HbA1c within the treatment group a stepwise linear mixed model was 
used. Factors considered were age, diabetes duration, baseline values of weight, HbA1c, insulin 
dose and the difference between fasting and postprandial C-peptide/glucose ratio (increment). To 
evaluate factors related to hypoglycaemia a stepwise logistic regression model was performed. 
The dependent variable was the occurrence of hypoglycaemia and the factors considered were 
age, diabetes duration, change in HbA1c, weight, insulin dose/kg and fasting C-peptide/glucose 
ratio. A power calculation was carried out. According to this, to detect a difference in HbA1c of 
0.8% between glimepiride/placebo treatment period, with an α error of 0.05 and a statistical 
power of 80%, a sample size of 41 patients was needed. 
 
Study IV 
Pearson´s correlation coefficients between reference glucose values and calculated mean CGMS 
readings were calculated. To assess agreement between the CGMS and reference method, Bland 
and Altman plotting [Bland et al. 1986] was used. An Error grid analysis was performed 
according to a new, modified consensus Error grid from 2000 [Parkes et al. 2000] which is based 
on the original Error grid [Clarke et al. 1987]. 
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RESULTS 
GLYCAEMIC CONTROL 
Glycaemic control in Study II 
 
Ten years after they had attended a diabetes course at the Diabetes Day Care Centre, the patients’ 
HbA1c had decreased (Fig. 7) from 7.41% to 6.96% (mean difference: -0.45; 95% CI: -0.73, -0.16; 
P = 0.002). Expressed in IFCC units, HbA1c had decreased from 67 to 62 mmol/mol. 
 
Figure 7. Change in HbA1c 
 
 
This improvement in glycaemic control despite a longer duration of diabetes had been achieved 
through an intensification of glucose-lowering treatment (Table 4 and Fig. 8), e.g. increased 
insulin use: at follow-up 74% were on insulin, alone or in combination with oral medication, 
compared to only 33% at baseline. 
 
Figure 8. Use of glucose lowering treatments in 1997/1998 and 2007. 
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Glycaemic effects of SU in Study I 
 
After withdrawal of SU, FPG increased by ≥ 40% in 4/25 patients and another four reported an 
increase in plasma glucose > 20 mmol/l during daytime. Together these eight subjects were 
referred to as “early SU restarters” (Fig. 9). At follow-up in median 6 weeks (range 4-8) after SU 
withdrawal, another twelve patients were restarted on SU because of deterioration in glycaemic 
control, and they thus were referred to as “late SU restarters” (Fig. 9). Considering early and late 
restarters together, 80% of the patients could be classified as SU responders. 
 
 
 
 
Figure 9. Classification of patients after SU withdrawal in Study I. 
 
 
 
HbA1c among the “late restarters” increased from 7.1% to 8.2% (64-75 mmol/mol; P < 0.001) at 
follow-up (Fig. 10), the median increase being 1.1%, (range 0.4-2.0%; IFCC 4-21 mmol/mol). 
 
 
Figure 10.  HbA1c before SU withdrawal (●) and at follow-up visit (●)  
 in each “late restarter”. The bars represent the CV for the analysis. 
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Glycaemic effects of SU in Study III 
HbA1c decreased from 7.0% to 6.4%, (63-56 mmol/mol; P < 0.001) three months after addition of 
glimepiride to insulin and metformin. The median decrease was 0.5% (5 mmol/mol) and ranged 
from -0.1% to 1.9% (1-20 mmol/mol), FPG decreased from 8.6 to 7.3 mmol/l (P < 0.01), (Fig. 11 
and 12). There was no change in HbA1c during placebo treatment. 
 
 
Figure 11. HbA1c (mean ± SD) presented according to treatment sequence. 
 
 
Figure 12. FPG (mean ± SD) presented according to treatment sequence. 
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The improvement in HbA1c after glimepiride addition was accompanied by a need to reduce 
insulin according to protocol to avoid hypoglycaemia. The insulin doses thus had to be reduced in 
23/43 of the patients by 2-100% (median 29%). In this subgroup, HbA1c decreased in median by 
0.6%. When comparing patients who had to reduce their insulin dose with those who did not, 
HbA1c at start of glimepiride was 6.7% vs. 7.4% (59 vs. 67 mmol/mol; P = 0.001). There was no 
relation between insulin dose/kg and insulin dose reduction. 
 
There were no differences in baseline variables between treatment sequence groups in this cross-
over study, except in FPG (9.3 vs. 8.4 mmol/l, P = 0.028), see figure 12; but HbA1c was similar 
between groups (7.1 vs. 7.2%, IFCC 64 vs. 65 mmol/mol; P = 0.855), see figure 11. Further, there 
was no effect in randomization sequence or in HbA1c (7.0% vs. 7.2%, 63 vs. 65 mmol/mol; 
P = 0.106) at the start of the two treatment periods. This was because patients starting with 
glimepiride and whose glycaemic control improved during this treatment period deteriorated in 
HbA1c during the washout period. 
 
 
β-CELL FUNCTION AND PREDICTION OF RESPONSE TO SU 
 
Study I 
 
When comparing patients classified as SU responders (N=20) with the non-responders (N=5), 
the responders had higher levels of basal fasting C-peptide (0.84 ± 0.44 vs. 0.41  ± 0.15 nmol/l; 
P < 0.05), with a large variation in the group. No other differences were observed between the 
groups at baseline (HbA1c, FPG, fasting or postprandial C-peptide/glucose ratio or increase in C-
peptide from fasting to postprandial, BMI or insulin requirement).  
 
In a prediction analysis the parameters associated with an increase in FPG when SU was with-
drawn was diabetes duration (P < 0.01) and insulin dose/kg (P = 0.02). There was a positive 
relation between the change in FPG (from baseline to the two-week visit) and diabetes duration 
(P < 0.01) as well as between the change and duration of SU treatment (P < 0.001). Patients with 
a longer duration had a more pronounced increase in FPG (Fig. 13), indicating that they had had 
more benefit from SU than those with a shorter duration. The insulin dose/kg correlated inversely 
with the increase in FPG i.e. patients needing a higher insulin dose did not seem to benefit from 
SU as much as those with a lower dose.  
 
The different insulin regimens (Table 5) or the use of metformin did not affect the changes 
observed in FPG and HbA1c following withdrawal of SU.  
 
In the SU responders, fasting C-peptide levels decreased from 0.84 to 0.53 nmol/l (P  < 0.001) 
after SU withdrawal, as compared with the non-responders in whom the concentration did not 
change significantly (0.42 vs. 0.41). The same was observed for the ratio C-peptide/glucose, 
which decreased significantly after SU withdrawal: in the fasting state from 0.104 to 0.050 
(P < 0.001) and postprandially from 0.130 to 0.076 (P < 0.001).  
  
  34 
 
Figure 13. Relation between change in FPG from study start to end of two week  
 withdrawal and duration of SU therapy (R2 = 0.26, P < 0.01). 
 
 
Study II 
After ten years there was a decrease in postprandial C-peptide and postprandial C-peptide/glucose 
ratio, as shown in figure 14. 
 
Figure 14. Change in postprandial C-peptide and C-peptide/glucose ratio 
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A positive titre (> 200 U/ml) of GAD antibodies was found in twelve patients (7%). The GAD-
positive patients differed from the GAD-negative in BMI, postprandial C-peptide and post-
prandial C-peptide/glucose ratio and their ratio decreased from 0.137 to 0.081 (mean difference: 
-0.056, 95% CI: [-0.11; 0.002], P = 0.056). If the twelve GAD-positive patients were excluded 
from the analyses, the decrease in the ratio was lower and non-significant (P = 0.139), but other 
parameters analysed were unaffected. 
 
All C-peptide measurements were negatively related to diabetes duration. In a simple linear 
regression model the strongest correlation was with postprandial values (Fig. 15). 
 
 
          
 
Figure 15. Correlation between postprandial C-peptide/glucose ratio and diabetes duration  
 
 
A multiple regression model was performed to evaluate the effects on long-term change in post-
prandial C-peptide/glucose. This regression model revealed that the baseline postprandial C-
peptide/glucose ratio was the most important independent variable (R2 = 45%; P < 0.001) for 
explaining the variation in long-term changes in the ratio. The second most important variable 
was insulin therapy (R2 = 7%; P < 0.001), while change in HbA1c from baseline to follow-up 
was the third most important variable (R2 = 5%; P < 0.001). An increase in HbA1c between 
1997/1998 and 2007 was associated with a decrease in postprandial C-peptide/glucose ratio 
(mean change: -0.056). The ratio remained essentially unchanged when HbA1c was decreased. 
The model explained 61% of the variance in long-term ratio C-peptide/glucose. 
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Long-term exposure to SU and β-cell function 
To assess a possible effect of SU treatment on β-cell function, patients in Study II were classified 
into three groups depending on SU exposure: continuously during ten years, periodically or never. 
These groups were used in the multiple regression analysis with the difference in ratio post-
prandial C-peptide/glucose between 1997/98 and 2007 as the outcome variable. Treatment with 
SU could not explain any of the observed variation in long-term change in postprandial C-
peptide/glucose (R2 = 0.1%, P = 0.89).  
 
Study III 
The ratio between C-peptide/glucose did not change during the placebo period but increased 
significantly with glimepiride, in the fasting state from 0.087 to 0.118 (P < 0.001) and post-
prandially from 0.123 to 0.173 (P < 0.001). 
If response to glimepiride was defined as a decrease in HbA1c of ≥ 0.5% (5 mmol/mol) or a 
reduction in total insulin dose of ≥ 20%, 29/43 patients (67%) met these criteria and they were 
classified as responders. When comparing the responders (N=29) to the non-responders (N=13), 
the responders were younger (64 vs. 68 years, P < 0.05) but no other differences were observed 
between the groups. 
To analyse factors at baseline that could be of value to predict response to glimepiride, a step-
wise multiple regression analysis was performed with the change in HbA1c as dependent 
variable. This analysis revealed that a larger increment i.e. the increase from fasting to post-
prandial values, in C-peptide/glucose ratio was associated with a more pronounced decrease in 
HbA1c (P < 0.001). Older age was associated with a smaller decrease (P < 0.05). These two 
variables together explained 26% of the variance in HbA1c. 
 
 
HYPOGLYCAEMIAS  
 
In Studies I, II and IV hypoglycaemia was not defined by protocol, and thus hypoglycaemia 
could only be correctly assessed in Study III.  
 
Hypoglycaemia by SMPG 
Patients performed SMPG every morning but also if symptoms of hypoglycaemia occurred. 
Minor hypoglycaemia, confirmed by SMPG, occurred in 22 patients. They reported a total of 124 
episodes during the 3+3 months, with the majority of these (74%) occurring during the 
glimepiride period. With glimepiride 21 patients reported altogether 92 episodes (1-8 episodes/per 
patient, except one subject who experienced 30 episodes) with a SMPG < 3.1 mmol/l. 
A stepwise logistic regression model revealed that variables relating significantly to hypo-
glycaemia in the glimepiride group was age and baseline fasting C-peptide/glucose ratio so that an 
increase in age by one year increased the odds of having an event by about 21 % (Odds ratio 1.21, 
CI: 1.05-1.49, P = 0.03) and an increase in fasting C-peptide/glucose by 0.01 decreased the odds 
with 31% (Odds ratio 0.69, CI: 0.48-0.89, P = 0.015). 
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Nocturnal hypoglycaemia by CGMS 
Glycaemia was monitored by CGMS for 72 hours at the end of each treatment period. CGMS 
monitoring could not be performed in 4 patients. When evaluating CGMS recordings between 
midnight and 6 AM, 4% of the recordings did not fulfil accuracy criteria and were not analysed. 
Six patients (15%) had two or more consecutive values < 3.1 mmol/l during the last three nights 
with placebo, the median time spent at these levels with placebo was 40 min (range 5-105). At the 
end of glimepiride treatment 15 patients (38%) had two or more consecutive values < 3.1 mmol/l 
and the median time spent at low glucose levels was 45 min (5-280). Notably, none of these 
recordings were associated with symptoms.  
 
 
ACCURACY OF CGMS  
All CGMS data were evaluated according to the quality criteria for optimal accuracy given by 
Medtronic [Gross et al. 2000] and 32 % of the data were excluded from further analysis. One 
hundred and three paired CGMS and glucose reference values from 12 patients were available, 
40% after 48 hours and 60% after 72 hours. A correlation coefficient of 0.80 (P < 0.001) was seen 
after 48 hours and a lower coefficient of 0.33 (P = 0.01) after 72 hours. Bland-Altman analyses 
[Bland et al. 1986] demonstrated that the dispersion of the values, expressed as mean ± 2SD, 
around the mean of differences was wider after 72 hours than after 48 hours.  
Plotting CGMS and glucose values according to the Clarke Error Grid analysis, which is used to 
assess the accuracy of a given glucose method with respect to the clinical decision process [Parkes 
et al. 2000], demonstrated that 100 % of data were within zones A and B after 48 hours with 60 % 
in zone A (Fig. 16, left panel). However, only 44 % were in zone A after 72 hours, in parallel with 
which 7 % of data were “clinically unacceptable” i.e. in zone D (Fig. 16, right panel). 
 
 
 
Figure 16. Clarke Error grid analysis comparing CGMS values to P-glucose after  
 48 hours (left panel) and 72 hours (right panel). 
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DISCUSSION 
 
ASSESSMENT OF INSULIN SECRETION IN CLINICAL PRACTICE – IS IT USEFUL? 
 
In clinical practice, tests for assessing β-cell function, i.e. insulin secretion, must be easy to 
perform. For this reason, fasting samples or simple stimulation tests have to be used. HOMA-B, 
using fasting insulin and glucose, is the most validated method and has been used in large clinical 
studies [UKPDS 1998; Kahn et al. 2006]. However it cannot be used in patients with insulin 
therapy and is thus mostly not applicable in patients with longer diabetes duration because it is 
these who receive insulin therapy. 
 
A commonly used parameter for evaluating endogenous insulin secretion is C-peptide but the 
interpretation of C-peptide values can be very difficult - because of the many factors influencing 
insulin secretion, which include prevailing glucose level, chronic glucotoxic effects of elevated 
glucose levels, and treatment with hypoglycaemic agents [Albareda et al. 2005]. C-peptide 
response to a stimulus is affected by the pre-stimulatory glucose level, and if glucose is acutely 
elevated in well-controlled type 2 patients, C-peptide response is enhanced [Gjessing et al. 1989] 
but when chronic hyperglycaemia and glucotoxicity exist, the insulin secretory response may be 
blunted [McFarlane et al. 2001; Buchanan 2003]. 
 
Since glucose is a major stimulant of C-peptide secretion [Brunzell et al. 1976], C-peptide values 
should be interpreted in the context of the prevailing glucose levels; and one approach to this is 
via the C-peptide/glucose ratio. Treatment with exogenous insulin is associated with a decrease in 
C-peptide concentrations, a finding that is probably related to lower glucose concentrations 
[Lindström et al. 1992]. This was also found in Study II, in which C-peptide levels decreased 
markedly over ten years in patients on insulin therapy. However, the C-peptide/glucose ratio 
remains unchanged during insulin therapy [Lindström et al. 1992; Albareda et al. 2005], which is 
in line with what was observed in Study II, where the ratio decreased only slightly in the insulin-
treated patients. 
 
An experimental study by Meier et al, recruiting patients who were to undergo pancreatic surgery, 
tried to assess what measure of insulin secretion showed the closest association with β-cell area 
[Meier et al. 2009]. Patients were given an oral glucose load and different measures of insulin 
secretion were obtained during a prolonged OGTT and β-cell mass was later collected during 
surgery. It was concluded that the C-peptide/glucose ratio showed the best correlation, while 
HOMA-B failed to predict β-cell area [Meier et al. 2009]. It was suggested that future studies 
should consider using the C-peptide/glucose ratio after oral glucose ingestion when evaluating β-
cell function over-time. 
 
In Study II long-term β-cell function was assessed as postprandial C-peptide/glucose ratio. Since 
no fasting values were obtained at baseline in 1997/98 it was not possible to calculate β-cell 
responsiveness at baseline or to use these measurements for evaluation of long-term β-cell 
function. Evaluating the relation between different C-peptide measurements with diabetes 
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duration and HbA1c at follow-up in Study II showed that postprandial C- peptide values related 
more closely to both diabetes duration and HbA1c than fasting values did. This was also the 
finding in another clinical study in which β-cell function was evaluated by using C-peptide 
[Haupt et al. 1999]. 
 
A meaningful assessment of C-peptide response to a stimulus such as a meal includes a 
consideration of the baseline C-peptide levels. When developing the indexes based on 
mathematical modelling for fasting ratio C-peptide/glucose and postprandial β-cell responsiveness 
(ΔC-peptide/Δglucose) Hovorka et al evaluated a simplified method using one or two point 
measurements of C-peptide and glucose values. They concluded that this easier approach could be 
used for assessing post-prandial insulin secretion [Hovorka et al. 2001]. Postprandial 
responsiveness is more closely related to diabetes duration and glycaemic control than fasting 
values are, as reported in other studies [Albarrak et al. 2002; Shim et al. 2006] in which β-cell 
function is evaluated by using the increment of C-peptide/glucose. 
 
To summarize, when evaluating insulin secretion by using C-peptide in patients with different 
glucose levels and glycaemic control, treated with different combinations of glucose-lowering 
drugs and insulin regimens, the use of the C-peptide/glucose ratio, reduces the influence of some 
of the confounders affecting the measurement. It seems that, although far from perfect, the ratio - 
especially postprandially - is more appropriate for evaluating insulin secretion in patients with 
type 2 diabetes. These measurements can be useful when β-cell function is being evaluated 
longitudinally in clinical studies. In clinical practice very low or high level of C-peptide can be 
helpful, mainly in the classification of diabetes, but only if interpreted in the context of prevailing 
glucose level and if the influence of long-term glycaemic control is considered. 
 
 
LOSS OF INSULIN SECRETORY CAPACITY IN TYPE 2 DIABETES  
– IS IT INEVITABLE? 
 
The reported loss of β-cell function, as assessed by HOMA-B, that was observed over time in the 
UKPDS has substantially affected the general view of type 2 diabetes as a disease characterized 
by a deterioration of β-cell function with time [UKPDS 1995]. However, the aims of the blood 
glucose control in the UKPDS were twofold: (1) to test the hypothesis that tight glucose control 
leads to a reduction in diabetes complications and (2) to evaluate whether there are any specific 
advantages or disadvantages with the three commonly used glucose-lowering therapies i.e. SU, 
insulin and metformin. Therefore, by protocol, the patients were kept on monotherapy with their 
allocated treatment even though a steady increase in fasting glucose was observed which in turn, 
not surprisingly, led to deterioration of glycaemic control as assessed with HbA1c. In the UKPDS, 
β-cell function was assessed as HOMA-B and it should be noted that the mathematical formula is 
such that HOMA-B decreases as FPG increases, unless there is a simultaneous increase in insulin 
concentration. As discussed earlier, the relationship between FPG and insulin secretion is 
complex and HOMA-B may not provide a “totally accurate view of the absolute ability of the 
pancreatic β-cell to secrete insulin” [Reaven 2009]. 
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In Study II changes in β-cell function, as assessed by postprandial C-peptide alone as well as by 
the C-peptide/glucose ratio, were described at baseline and after ten years. One important finding 
was that even though postprandial C-peptide was significantly lower after ten years, the ratio was 
only marginally and non-significantly lower. Further, considerable variation between patients was 
observed.  
 
In contrast to the UKPDS findings the patients in Study II showed improved glycaemic control 
over ten years, most likely due to an increased and intensified use of glucose lowering therapies. 
The importance of considering glycaemic control when interpreting changes in β-cell function, 
assessed by using C-peptide values as in Study II, is highlighted by the finding that when HbA1c 
increased C-peptide/glucose decreased and if glycaemic control improved, the ratio remained 
unchanged. A longer diabetes duration at follow-up was associated with lower C-peptide and 
lower ratio C-peptide/glucose values, and thus the results are consistent with those in other cross-
sectional studies [Clauson et al. 1994; Haupt et al. 1999; Shim et al. 2006; Funakoshi et al. 2008]. 
Zangeneh et al reported that insulin secretion as measured by C-peptide declined with increasing 
diabetes duration in approximately 50% of patients, but increased or remained constant in the 
other half in a 12 year follow-up study in which glycaemic control was improved and GAD 
antibody-positive patients were excluded [Zangeneh et al. 2006]. The results are in concordance 
with those in Study II, since we observed similar patterns in the change in insulin secretion. In a 
20 year prospective study of consecutively diagnosed diabetes patients in Sweden [Ekholm et al. 
2012], insulin secretion, assessed as fasting C-peptide was preserved in GAD antibody negative 
patients, when glycaemic control was improved at the same time as a result of more intensive 
treatments. In Study II 12 patients (7%) tested GAD-antibody-positive, a prevalence similar to 
that observed in older patients in the Finnish Botnia study [Tuomi et al. 1999]. GAD-antibody-
positivity in Study II was associated with lower C-peptide/glucose ratios and also with a more 
pronounced decrease in C-peptide/glucose after ten years. Further, when we excluded GAD-
antibody-negative patients from the analyses, the ratio did not decrease over ten years.  
 
Deterioration of β-cell function does not seem to be completely irreversible. In a study where four 
weeks of intensive treatment with insulin was given to a group of patients with hyperglycaemia, 
some with diabetes duration of 12 years, there was marked increase insulin secretion which 
persisted for at least two weeks after insulin treatment was stopped [Andrews et al. 1984]. 
However, there was “considerable patient-to-patient variation in the degree to which insulin 
action was enhanced” [Andrews et al. 1984]. The positive effects on glycaemic control, observed 
after weight reduction surgery, with remission of type 2 diabetes, in some patients for up to two 
years or more, also support the notion that deterioration of β-cell function in type 2 diabetes is not 
irreversible [Buchwald et al. 2009]. 
 
To summarize, it seems that the decline in insulin secretory capacity is variable, related to 
glycaemic control and is not inevitable in all patients. 
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SU IN PATIENTS WITH A LONG DURATION OF DIABETES – IS IT WORTHWHILE? 
 
An implication of the heterogeneity regarding loss of β-cell function with preserved insulin 
secretion in many patients is that SU treatment could be effective even after a long duration of 
diabetes. This issue has not been specifically addressed in earlier clinical studies. 
 
In most studies on combination therapy with SU and insulin, diabetes duration has varied 
substantially, and duration has not been specified as an inclusion criterion. An Australian study 
concluded that patients with a duration of insulin therapy > 8 years are unlikely to benefit from 
adding SU to insulin [Lewitt et al. 1989]. This opinion, i.e. that SU not is advantageous in patients 
with a longer duration of type 2 diabetes, seems to be shared by others [Massi-Benedetti et al. 
2008; Raskin 2008]. It is true that SU therapy often fails to maintain glycaemic levels when used 
as monotherapy, termed “SU failure” [Matthews et al. 1998]. Further, older studies investigating 
the efficacy of combined SU + insulin treatment have been short-term, and the long-term efficacy 
of SU in combination therapy has not been clarified. However, two large prospective studies have 
shown durability of combined SU and insulin therapy [Wright et al. 2002; Patel et al. 2008]. In a 
sub-study of the UKPDS [Wright et al. 2002], using a modified protocol, it was allowed to add 
insulin in patients allocated to SU if maximal doses of SU did not maintain FPG < 6.0 mmol/l. 
After six years 52% of the patients required combination therapy, and SU + insulin resulted in a 
lower HbA1c (6.6% vs. 7.1%; 49 vs. 54 mmol/mol) than that in the group treated with insulin 
monotherapy. The ADVANCE study [Patel et al. 2008] used gliclazide (modified release), a SU 
compound, as the basis for intensive glucose-lowering treatment adding other drugs as required to 
achieve a goal of HbA1c < 6.5% (48 mmol/mol). The patients included had a mean duration of 
diabetes of around eight years at baseline and at the end of follow-up, after a median of five years, 
almost 74% had metformin added to SU and insulin had been added in 40.5%, reaching an HbA1c 
of median 6.4% (46 mmol/mol). While the primary outcome in the ADVANCE study was not the 
efficacy of SU therapy, the results indicate that glycaemic control with combined SU and insulin 
can be maintained. The ability of SU to maintain its positive effect on glucose control in patients 
with a longer duration of diabetes was investigated in Study I and Study III. 
 
In Study I - which recruited patients with a median diabetes duration of 19 years and at least five 
years of SU treatment - withdrawal of SU clearly resulted in a worsening of glycaemia in two 
thirds of the 25 patients. SU withdrawal is a procedure used in earlier diabetes studies [Nobels et 
al. 1989; Lev-Ran et al. 1998; Landstedt-Hallin et al. 1999]. Withdrawal studies can be designed 
either as a randomized study where patients are randomized to either stop or continue using the 
medication [Landstedt-Hallin et al. 1999; Iyer et al. 2008] or, as in Study I, where all patients 
stop SU and the effect on glycaemia is observed for each individual patient. In the two earlier SU 
withdrawal studies by Lev-Ran et al and Landstedt-Hallin et al, in patients with diabetes duration 
of mean 13.5 and 9.9 years respectively, SU withdrawal resulted in an increase in FPG of 
approximately 40% in 80% of patients after a follow-up of four and 17 weeks respectively. In 
Study I the follow-up was only two weeks, at which time FPG had increased by over 40% in 4/25 
patients, less than in the two early-mentioned studies. However, the observation time of two 
weeks in Study I was most likely too short for metabolic deterioration to occur and moreover, the 
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majority of patients in Study I were treated with glibenclamide, which is eliminated slowly 
[Jonsson et al. 1994] and may have long-lasting active metabolites [Jonsson et al. 2001].  
 
More recently the efficacy of SU in combination with insulin in long-standing diabetes was 
evaluated in a Japanese cross-over, withdrawal study [Yokoyama et al. 2010] of patients with a 
mean diabetes duration of 17 years and good glycaemic control, on treatment with combined 
metformin, glimepiride and insulin. The patients had been on SU treatment for ten years with the 
addition of insulin the previous five, very similar to the patients in Study I. Three months after 
withdrawal, glycaemic control deteriorated significantly in the discontinuation arm, from 7.0% to 
8.1% (NGSP values calculated from JDS; IFCC 53 to 65 mmol/mol) i.e. HbA1c increased by 
1.1% (12 mmol/mol) which is identical with the result in Study I, in which HbA1c increased in 
median 1.1% in the “late-restarters” after SU withdrawal. The authors concluded that the efficacy 
of glimepiride did not decline severely after more than ten years of diabetes and moreover, when 
they stratified subjects according to diabetes duration, patients with a duration > 17 years 
experienced similar worsening of HbA1c when SU was withdrawn [Yokoyama et al. 2010].  
 
In Study III glimepiride was added to on-going insulin and metformin in patients with a known 
diabetes duration ≥ 10 years. The results showed significant reduction in HbA1c three months after 
glimepiride addition even though insulin doses had to be reduced in approximately 50 % of the 
patients. Adding SU to insulin therapy was investigated in another placebo-controlled cross-over 
study, where the patients had a mean diabetes duration of 15 years and an insulin requirement of 
≥ 40 U/day [Feinglos et al. 1998]. Glipizide addition resulted in a rapid and substantial improve-
ment in glycaemic control despite significant insulin dose reductions in the insulin + glipizide 
group. In a small, observational study the efficacy of adding gliclazide in patients in routine 
diabetes care, with poor glycaemic control (HbA1c 9%; 75 mmol/mol) and treated with different 
insulin regimens and metformin, mean diabetes duration of 13 years, resulted in a reduction in 
HbA1c of 1.4% (15 mmol/mol) after 3 months [Brown 2006]. In a Japanese study glimepiride was 
added to insulin in patients with a mean diabetes duration of 19 years and poor glycaemic control 
(JDS HbA1c 8.4%; 74 mmol/mol) which resulted in a decrease in HbA1c of 1.1% (12 mmol/mol) 
after 12 weeks, however, without significant insulin dose reductions during this period [Ose et al. 
2005]. The patients were followed for 18 months and the improvement in HbA1c was sustained 
during this period while insulin doses were significantly reduced after three months in the group 
where glimepiride had been added [Ose et al. 2005]. In Study III HbA1c decreased in median 
0.5% (IFCC 5 mmol/mol) during three months treatment with glimepiride and the insulin dose 
had to be reduced in 23 patients, by 2-100 % (median 29 %) as an effect of glimepiride 
stimulating endogenous insulin secretion. Comparing the results in Study III with those of Ose et 
al, it is notable, that baseline HbA1c was higher in the Japanese study, which allows for a greater 
reduction in HbA1c after SU addition. In Study III patients who had to reduce their insulin dose 
after addition of glimepiride because of low glucose values and/or hypoglycaemia had a 
significantly lower HbA1c at baseline, 6.7% vs. 7.4%, (59 vs. 67 mmol/mol). One third of the 
patients had a baseline HbA1c of 6.5% or lower (57 mmol/mol) and therefore no substantial 
reduction in HbA1c could be expected. This subgroup had a median decrease in HbA1c of 0.3% 
together with an insulin dose reduction of 30%, compared to those with a baseline HbA1c > 6.5% 
in which HbA1c decreased by 0.6% and the insulin dose was reduced to a lesser extent. 
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One could argue that a reduction in HbA1c of 0.5%, the median reduction achieved in Study III, is 
rather small and not clinically important. However, epidemiological data from UKPDS suggest 
that a reduction of HbA1c of 0.5% might equate to 11.5% reduction of diabetes complications 
[Stratton et al. 2000]. 
 
In summary, since SU in long-term combination therapy with insulin and metformin appears to be 
effective in many patients there is no rationale for routinely withdrawing the SU component after 
many years of combination therapy. However, a period of SU withdrawal, to determine whether 
the drug is still beneficial, can easily be performed and if glycaemia worsens it is worthwhile to 
recommence the medication. Furthermore, in patients with type 2 diabetes treated with metformin 
and insulin, addition of glimepiride to on-going therapy if the individualized glycaemic target is 
not reached may be worthwhile, even after many years of diabetes.  
 
 
WHAT ARE THE POSSIBLE DISADVANTAGES OF ADDING SULPHONYLUREA TO 
INSULIN AND METFORMIN? 
 
The well-known disadvantages of SU are weight gain and hypoglycaemia. In the present studies 
no effect on weight was observed. In Study III, glycaemic control improved which can be 
associated with weight gain, but insulin doses were reduced simultaneously, and this may have 
promoted weight stability. Hypoglycaemic events were evaluated in Study III and this will be 
discussed below.  
 
Another potential disadvantage of SU treatment was extensively debated during the 1990’s when 
the mechanism of action of SU was described i.e. the binding to ATP-sensitive potassium 
channels that also are found in the myocardium [Ashcroft et al. 1992]. Since these channels are 
believed to be important for what is termed ischaemic preconditioning of the heart, partly 
protecting the heart during ischaemic events, blocking of them might be disadvantageous in some 
situations [Engler et al. 1996]. During the past decade this debate has faded and the clinical 
relevance of these molecular mechanisms can be questioned, especially since long-term data from 
the UKPDS also showed a protective effect with regards to myocardial infarction and 
cardiovascular death also in the group treated intensively with SU [Holman et al. 2008]. 
 
 
Increased risk of hypoglycaemia? The use of CGMS for assessment?’ 
One negative effect of intensive glycaemic control in patients with diabetes is the increased rate of 
hypoglycaemia [1993; Pedersen-Bjergaard et al. 2004; Mannucci et al. 2009; Zhang et al. 2009]. 
The incidence of hypoglycaemia increases with duration of diabetes and of insulin therapy 
[Henderson et al. 2003; Donnelly et al. 2005]. Hypoglycaemia has been considered a much more 
serious and common problem in type 1 diabetes[DCCT 1993; ter Braak et al. 2000] than in type 2 
diabetes but if patients with type 1 and patients with type 2 are matched for duration of insulin 
treatment the hypoglycaemia rate differs little [Hepburn et al. 1993].  
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The SU used in Study III was glimepiride. This compound is associated with a lower frequency 
of hypoglycaemia than e.g. glibenclamide is [Holstein et al. 2001] and glimepiride is one of the 
two SU compounds recommended in Swedish guidelines [Läkemedelsverket 2010]. One caveat 
when comparing hypoglycaemia rates between studies is the lack of consensus on a common 
definition of biochemical hypoglycaemia [Service 1995]. Thus various glucose levels around 
3 mmol/l have been defined as hypoglycaemia, and we use the same definition as was used in an 
earlier study [Holman et al. 2007] for both SMPG and CGMS. No major hypoglycaemia occurred 
during study III but adding glimepiride to insulin and metformin resulted in a higher frequency of 
minor hypoglycaemia, both when assessed as SMPG and as CGMS during nighttime, than 
placebo did. However, six of the 21 patients who reported minor hypoglycaemia with SMPG 
< 3.1 mmol/l, had only one episode during three months of glimepiride addition. Note also that all 
patients in Study III were on insulin and forty percent were treated with complex insulin 
regimens, using > 3 insulin injections/day: this has been associated with an increased risk of 
hypoglycaemia [Holman et al. 2007].  
 
In previous studies long diabetes duration has been associated with an increased risk of hypo-
glycaemia [Henderson et al. 2003; Akram et al. 2006] but this was not found in Study III. In the 
stepwise regression model used to evaluate factors related to hypoglycaemia, diabetes duration 
was not related to its occurrence. However, older age was associated with a higher risk of hypo-
glycaemia, and low endogenous insulin secretion at baseline was also significantly associated 
with an increased risk. This is in line with other reports [Shorr et al. 1997; UK Hypoglycaemia 
Study Group 2007]. The incidence of hypoglycaemia has been related to the level of glucose 
control [Miller et al. 2001; Henderson et al. 2003], but in Study III HbA1c, - neither baseline nor 
change or final level - did predict the occurrence of hypoglycaemia.  
 
CGMS provides data on nighttime glycaemic profiles that are difficult to obtain with SMPG and 
thus CGMS could be valuable for detecting hypoglycaemia in type 2 diabetes patients. This is 
particularly important in view of the evidence suggesting that older people have fewer and less 
intensive symptoms of hypoglycaemia [Brierley et al. 1995] and that the difference, between the 
glucose level at which hypoglycaemic symptoms are generated and the onset of cognitive 
function, is lost in older patients [Matyka et al. 1997]. It is speculated that the aged brain is less 
able to perceive physiological and cognitive alterations associated with hypoglycaemia [Bremer et 
al. 2009]. Hypoglycaemia might go unrecognized in older people [McAulay et al. 2001], 
especially during nighttime, and this may be deleterious because recurrent low glucose values 
may result in impaired awareness of hypoglycaemia [Segel et al. 2002]. The impaired perception 
of hypoglycaemic symptom in elderly people increases the risk of severe hypoglycaemia 
[Schopman et al. 2011].  
 
Study IV was performed in the early clinical era of CGMS and the durability of the sensor 
accuracy of nocturnal CGMS readings was studied for the first sensor model. CGMS was initially 
introduced as a useful tool to detect unrecognized nocturnal hypoglycaemia [Boland et al. 2001; 
Chase et al. 2001]. The accuracy and performance of the first sensor system were questioned by 
McGowan et al who documented that when comparing simultaneous glucose reference values 
with CGMS readings, CGMS generated lower nocturnal values in well-controlled type 1 diabetic 
patients [McGowan et al. 2002]. In most studies in which sensor accuracy was tested, no 
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confirmatory reference values were used, and the sensor accuracy was evaluated by agreement of 
paired data from capillary glucose values used for calibration and sensor reading. This procedure 
may overestimate the accuracy of sensor performance [Djakoure-Platonoff et al. 2003]. Whether 
sensor performance remained stable over time [Gerritsen 2000] was a crucial question. This was 
the background to study IV, and indeed, the results did show decreased sensor accuracy during the 
third night of registration. 
 
After Study IV was published, new sensor products have been developed. The performance and 
accuracy of the Medtronic REAL-time CGMS, using the same sensor as was used in Study III, 
was investigated in a large study which showed sensor readings in close agreement with glucose 
meter values; and when stratifying for duration of sensor wear for up to 72 hours, the sensor 
performed well [Mastrototaro et al. 2008]. Some studies suggest that sensor performance remains 
stable over three to seven days [Guerci et al. 2003; Chlup et al. 2006; Wong et al. 2006]. In one 
study in which CGMS readings were compared to reference P-glucose values, sensor accuracy 
did not deteriorate over nine days of continuous use [Iscoe et al. 2012]. The accuracy of a sensor 
is lower in the hypoglycaemic range [Klonoff 2005]. However, when hypoglycaemia is induced 
in clamp studies, CGMS has accurately reflected P-glucose down to 3.3 mmol/l [Caplin et al. 
2003] tracking changes in glucose very well [Monsod et al. 2002]. 
 
When CGMS recordings between midnight and 6 AM in study III were analysed, six patients had 
two or more consecutive values < 3.1 mmol/l during the last three nights with placebo and the 
median time spent at these levels was 40 min (5-105). At the end of glimepiride treatment 38% 
(15/39) of the patients had values < 3.1 mmol/l and the median time spent at low glucose levels 
was 45 min (5-280). None of these recordings were associated with symptoms. Asymptomatic 
hypo-glycaemic episodes during nighttime have also been reported from other CGMS studies in 
type 2 patients [Weber et al. 2007; Hanefeld et al. 2009]. A Spanish study reported that 43% of 
patients treated with insulin and oral agents had asymptomatic nighttime hypoglycaemia, detected 
by CGMS [Chico et al. 2003] and in an Australian report, where well-controlled (HbA1c 6.2%, 
IFCC 44 mmol/mol) older patients (mean age 74 years) on oral therapy including SU, were 
studied with CGMS, 56% patients had glucose levels < 2.2 mmol/l, mostly during nighttime and 
all unrecognized by the patient [Hay et al. 2003]. The duration of hypoglycaemia in the latter 
study was 78 min (20-305 min). Similar results were reported by McNally et al with at least one 
episode of glucose < 3.5 mmol/l at night in 51%-66% of patients in a study comparing two insulin 
regimens; and the majority of these events were unrecognized [McNally et al. 2007]. The 
conclusion is that well-controlled type 2 patients probably have a significant number of un-
recognized hypoglycaemias during nighttime, but whether this reflects clinically relevant hypo-
glycaemia could be debated. However, the use of CGMS in Study III provided information 
unobtainable with SMPG and allowed for therapeutic decisions in some patients that would 
otherwise not have been made. 
 
To conclude, older patients with type 2 diabetes with long duration of insulin therapy, complex 
insulin regimens, and low endogenous insulin secretion [UK Hypoglycaemia Study Group 2007; 
Amiel et al. 2008] are at the same risk of developing hypoglycaemia as people with type 1 
diabetes. Hypoglycaemic events in older people may be overlooked because of fewer symptoms 
perceived, further increasing the risk of severe hypoglycaemia. Against this background, CGMS 
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could be justified in a subgroup of patients with type 2 diabetes, selected as being at high risk of 
developing hypoglycaemia. However, the CGMS systems today are expensive for extensive 
routine clinical use and the technique may also be too complicated for older people to handle. 
Although sensor performance has undergone improvements, accuracy has been sparsely evaluated 
by comparing reference plasma glucose and sensor readings. More evidence regarding the 
usefulness of CGMS for type 2 diabetes is also needed, although small studies do show reduced 
frequency of hypoglycaemia and time spent at low glucose levels with the use of CGMS [Garg et 
al. 2006; Weber et al. 2007].  
 
 
Can SU accelerate the deterioration of β-cell function? 
There has long been much concern that treatment with SU could hasten the deterioration in β-cell 
function. There are data showing that glibenclamide can induce β-cell apoptosis [Maedler et al. 
2005], but there may be differences between SU compounds with respect to function and survival 
of cultured human islets. Thus, glibenclamide has more deleterious effects than glimepiride does 
[Del Guerra et al. 2005]. Gliclazide was shown in one study not to induce apoptosis [Sawada et al. 
2008] or could even protect β-cells from apoptosis [Del Guerra et al. 2007]. These differences are 
probably related to the more transient binding to the SU receptor with glimepiride and gliclazide. 
However, whether these findings translate into in vivo conditions and are of clinical relevance is 
not clear. It has also been suggested that SU could stress β-cells by increasing insulin secretory 
demand, while elevated levels of IAPP [Rachman et al. 1998], the polypeptide involved in 
formation of islet amyloidosis, and of proinsulin, proposed to be a sign of stressed beta-cells, have 
been associated with SU therapy [Pfutzner et al. 2006]. 
 
A less discussed but important finding from the UKPDS was, that the observed loss of β-cell 
function, assessed by HOMA-B, occurred at the same rate regardless of treatment used, suggest-
ing that none of the therapies evaluated in UKPDS were more harmful to β-cells and that factors 
other than treatment modality contribute to the process [UKPDS 1998]. In contrast, a possible 
harmful effect of SU on β-cells was put forward in the more recent ADOPT study, in which the 
glycaemic durability of rosiglitazone, metformin and glyburide monotherapy and changes in β-
cell function, assessed with HOMA-B, were studied over four years [Kahn et al. 2006]. The 
deterioration in glycaemic control and decrease in HOMA-B was greatest in the glyburide group 
and the authors conclude that it was the more rapid loss of β-cell function that led to the increase 
in FPG and HbA1c (the difference in HbA1c between rosiglitazone and glyburide was 0.4%) in 
patients allocated to glyburide. However, taking into account the role of insulin and glucose in the 
formula of HOMA-B, an assumption could be that rosiglitazone, an insulin sensitizer, lowers FPG 
to a greater extent [Abbasi et al. 2011], which could partly, account for some of the difference in 
HOMA-B. After the ADOPT study was presented the interpretation of the results regarding SU 
have been questioned by some authors [Al-Ozairi et al. 2007; Yki-Järvinen 2007; Riddle 2010] 
giving a more positive view of the usefulness of SU. 
 
A beneficial effect of insulin compared to SU on insulin secretion and glycaemic control was 
reported from a Swedish group [Alvarsson et al. 2003]. In newly diagnosed type 2 diabetic 
patients, early insulin treatment resulted in a more pronounced C-peptide response to glucagon 
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after one and two years as compared to treatment with a low dose of glibenclamide. The degree of 
glycaemic control between the groups varied, with lower HbA1c in the group treated with insulin, 
which complicate the interpretation of the observed changes in β-cell function. 
 
In Study II long-term exposure to SU therapy and change in β-cell function were studied. The 
patients were classified into three groups depending on SU exposure: continuously during ten 
years, periodically or never. Relation to change in postprandial C-peptide/glucose was analysed in 
a regression model. The conclusion was that treatment with SU did not have any effect on change 
in β-cell function. 
 
Adult patients that are antibody-positive, i.e. have latent autoimmune diabetes in adults (LADA), 
a form of type 1 diabetes that initially presents as a clinical type 2 diabetes [Landin-Olsson 2002]. 
LADA is characterized by a slowly onset, and these patients probably have a faster β-cell failure 
rate, increasing the likelihood of insulin requirement [Turner et al. 1997]. LADA prevalence 
among patients with a clinical diagnosis of type 2 diabetes varies between 10-20% [Pozzilli et al. 
2001]. The optimal treatment for these patients has not been established, but SU is probably not 
advisable since they might promote β-cell destruction here, and the general recommendation is 
insulin therapy, which might better preserve β-cell function [Maruyama et al. 2008].  
 
 
WHO BENEFITS FROM SULPHONYLUREA AFTER MANY YEARS OF DIABETES? 
 
In both Study I and Study III one of the aims was to identify clinically useful markers or 
predictors of long-term responsiveness to SU but no such predictors were found. These results are 
in line with the conclusion from several studies in the 1980’s [Groop et al. 1986; Riddle et al. 
1989] and 1990’s [Ravnik-Oblak et al. 1995; Lev-Ran et al. 1998; Trischitta et al. 1998; 
Landstedt-Hallin et al. 1999], namely, that it is difficult to find clinical or metabolic variables that 
predict glycaemic response to combination therapy. A review article [Lebovitz et al. 1990] 
suggested that patients with a BMI 25-35 kg/m2 with poor glycaemic control on modest or high 
doses of insulin and significant C-peptide secretion when stimulated by nutrients are likely to 
respond to SU. Interestingly, duration of diabetes per se is not mentioned as a negative fact in the 
review although it is generally held that SU therapy is not effective after many years of diabetes. 
The finding in Study I, that the factors related to preserved SU responsiveness were a long 
duration of diabetes and of SU therapy, support the notion that SU compounds can in fact be 
effective despite many years of diabetes. The participating subjects in Study I were patients who 
had been exposed to insulin and SU over a long period as their diabetes duration was in median 
19 years, and they had been on a SU component for 15 years, combined with insulin for 10 years. 
The observation that long duration of diabetes and duration of SU therapy were both positively 
related to SU responsiveness, a result which is in concordance with findings from the SISU 
(Scandinavian Insulin-Sulphonylurea) study [Landstedt-Hallin et al. 1999]. The increase in FPG 
after SU withdrawal in Study I was more pronounced in patients with longer duration of diabetes 
indicating that SU was more effective the longer a patient had suffered from diabetes. This may 
seem to be a paradox. However, it could reflect the heterogeneity of type 2 diabetes and one 
possible explanation could be that patients with a slower rate of β−cell deterioration had been able 
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to manage longer on oral therapy. It could also reflect a selection bias, since it is possible that 
primary care physicians would not change a seemingly beneficial treatment in patients treated 
with SU for many years. Furthermore, patients with a lower insulin dose/kg at baseline in Study I 
had a more pronounced increase in FPG. A possible explanation for this could be that patients 
with lower insulin doses were more dependent on the SU compound for maintaining glucose 
control. In Study III older age was negatively related to response to glimepiride, which may 
relate to the general deterioration of β-cell function associated with aging [Chang et al. 2003; 
Scheen 2005].  
 
Measurements of C-peptide would seem appropriate to use when trying to predict response to SU 
since a residual β-cell function is the prerequisite for a beneficial effect of SU therapy [Falko et al. 
1985; Castillo et al. 1987]. However, in Study III it was found that the response to glimepiride 
was not related to fasting C-peptide or C-peptide/glucose and this is in line with earlier studies on 
SU combined with insulin [Riddle et al. 1989; Landstedt-Hallin et al. 1999]. The increment in C-
peptide or ratio C-peptide/glucose - from fasting to postprandial - that reflects the ability of β-cells 
to increase insulin secretion could, at least, theoretically be more informative. When these values 
were evaluated in Study III the increment in C-peptide/glucose ratio at baseline was related to a 
positive response to glimepiride explaining 12% of the variance in HbA1c and the increment in 
ratio also related positively to glimepiride response in a Japanese study [Yokoyama et al. 2010]. 
 
To summarize long duration of diabetes and of SU therapy predicted a continued beneficial effect 
of SU, which lends further support to our earlier conclusion, namely that SU are effective in long-
term combination with insulin. Neither C-peptide alone, the ratio C-peptide/glucose or the 
increment of the ratio may be considered clinically useful predictors of response to SU therapy in 
patients with long-standing diabetes. 
 
 
THE GLOBAL USE OF SULPHONYLUREAS – WHY DIFFERENCES? 
 
Sulphonylurea compounds have been one of the most commonly used oral medications for 
glucose-lowering in type 2 diabetes worldwide. They were introduced more than half a century 
ago and it is unlikely that large studies focusing on these agents will be performed, especially now 
that newer treatments are coming onto the market. 
 
The use of SU varies substantially between countries, with an apparent large variation in 
therapeutic traditions rather than in treatment guidelines. These almost always include SU as a 
treatment option [IDF 2006; Home et al. 2008; Socialstyrelsen 2010; ADA 2012; Inzucchi et al. 
2012]. In the ongoing GUIDANCE study (Guideline Adherence to Enhance Care), which is 
seeking to assess the quality of care of people with type 2 diabetes and adherence to guideline 
recommendations, data from eight European countries, including Sweden have been collected 
[Stone et al. 2010]. The use of SU was lowest in Sweden with only 19% SU treated patients, 
compared to 46% in France and 33% in the whole sample [Khunti 2012]. The data for Sweden are 
confirmed by recent data from the Swedish National Diabetes Register, showing that 
approximately 18% of patients are treated with a SU compound [Ekström et al. 2012]. In many 
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developing countries SU therapy is probably more common. Thus in many African countries the 
use of SU has been reported to be around 60% [IDF 2008]. The many possible reasons for these 
differences including available resources for health care, national or regional prescribing 
traditions and perhaps also the influence of misconceptions about the utility of old drugs and 
proposed disadvantages e.g. that SU compounds accelerate β-cell loss.  
 
In review articles on pharmacological treatment of type 2 diabetes it is stated that SU compounds 
are effective, safe, inexpensive [DeFronzo 1999; Del Prato et al. 2006; Bolen et al. 2007] and 
cost-effective [Gray et al. 2000]. In many less well-resourced countries the increasing costs for a 
growing number of people with diabetes and their care is a critical issue e.g. in the selection of 
drugs. The IDF Global Guidelines for the treatment of type 2 diabetes state that “in many parts of 
the world the implementation of particular standards of care is limited by lack of resources” 
[IDF 2006]. The IDF recommends metformin and SU and conclude that “cheap generic versions 
of these drugs are available, and their glucose-lowering capacity is not surpassed by any newer 
drug, at least on a population basis” [IDF 2006].  
 
To summarize it is difficult to explain why there are such large variations in the use of SU but the 
differences do not appear to be based on their efficacy or cost. 
 
 
FUTURE PERSPECTIVES 
 
The work presented in this thesis has tried to elucidate a few questions regarding the use of SU 
in type 2 diabetes, especially in patients with a longer duration of the disease. Mainly two issues 
have been addressed and they concern how we can increase the translation of research results 
into clinical practice to improve the medical care of patients with type 2 diabetes.  
 
First, there is a considerable variation between individual patients in the loss of β-cell function 
over time and more studies are needed to investigate by what mechanism responsiveness to SU 
may be preserved over several years of treatment. The individual variation in the rate of β-cell 
loss makes the practice of routinely withdrawing SU in patients after many years of diabetes 
questionable. However a controlled period of withdrawal can give information about the 
usefulness of SU in an individual patient. It may also be worthwhile to try SU as an add-on 
therapy in patients who are not reaching their glycaemic goals on metformin and insulin.  
 
Secondly, hypoglycaemia remains a limiting factor for achieving good glycaemic control of 
diabetes. Intensification of glucose-lowering therapy with insulin and SU in type 2 diabetes 
leads to higher incidence of hypoglycaemic events, many of which are undetected, and this may 
in turn provoke major vascular events in elderly patients [Zammitt et al. 2005]. Meticulous 
prevention of hypoglycaemia in patients at risk is therefore advocated and in this context the use 
of CGMS may prove helpful. Carefully conducted clinical studies are needed to assess the 
accuracy and efficacy of such systems in type 2 diabetes patients at risk. 
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CONCLUSIONS 
• Sulphonylureas are effective when combined with insulin even in patients with 
long-standing type 2 diabetes and there seems to be no rationale for routinely 
withdrawing the SU component after many years of combination therapy. 
 
• β-cell function, assessed as the ratio of postprandial C-peptide/glucose, decreased 
over an observation period of ten years but long-term treatment with SU was not 
associated with are more pronounced decline in β-cell-cell function. 
 
• Add-on therapy with glimepiride to insulin + metformin treatment in patients with 
long diabetes duration was effective in lowering HbA1c and/or reducing the need 
for exogenous insulin. 
 
• Careful evaluation of nocturnal CGMS registrations in type 2 patients with 
reference plasma glucose assessments may be advocated to ascertain the accuracy 
of such readings over time. 
  51 
ACKNOWLEDGEMENTS 
Finally, I wish to express my sincere gratitude and appreciation to everyone who has supported 
me on my journey to becoming a PhD. In particular I would like to thank: 
All the patients who participated voluntarily in the clinical studies forming the basis for this work. 
I appreciate the hours you spent coming to repeated visits to the clinic. Without each and every 
one of you this thesis would not exist. 
Lena Landstedt-Hallin, my main supervisor. Your qualities as a person are invaluable. Your great 
knowledge in the field of diabetes, combined with your ability to inspire and encourage, have 
guided me throughout the challenges of writing this thesis. Our patients’ wellbeing is your top 
priority, both in daily practice and in research. Thank you for your precious support with every-
thing and for your friendship! Now I hope you will have more time for your new grandchildren 
and for another passion of yours – genealogy! 
Per-Eric Lins, my co-supervisor. Your great experience of diabetology and your wisdom have 
immensely supported my work, as has your precise scientific advice which has put me in the right 
direction. Thank you also for the entertaining lunches we’ve enjoyed together at the hospital over 
the past few years. 
Ulf Adamson, my co-supervisor, thank you for your creative ideas and valuable reflections on my 
work and for giving me all needed support.  
Maaria von Heijne, co-author in Study IV, colleague and friend. Thank you for sharing the work-
load and for struggling with the endless Excel charts. And for good laughs in “Sockerkompaniet”. 
Associate Professors Gun Jörneskog and Håkan Wallén, for your support always when needed; 
Gun, for trying your hardest to arrange the most suitable ways for me to do my research work. 
Former and present heads of the department of medicine at Danderyd Hospital Carl-Göran 
Ericsson and Karin Malmqvist for providing me with the working facilities I needed. 
Lena Gabrielsson, for excellent work handling the patients, and especially for your contributions 
in the GLIM study. You kept the dropout rate near to zero. Thank you, too, for all the “extras”. 
Kerstin Bergqvist, for your thorough work on all my studies and your knowledge of CGMS has 
been very helpful. 
Jakob Bergström, statistician and co-author in Study II, for teaching me the mysteries of statistics. 
Marcus Thuresson for your help in compiling the statistics in the GLIM study. 
All my colleagues and friends at Endokrin at Danderyd Hospital: 
Maria Uhrenius and Inger Friberg for your belief in my abilities and for being the best colleagues 
one can have; Lena Hellström for nice early-morning walks in the forest with the dogs, which I 
hope will continue! Anna von Döbeln for your genuine interest in my work and for being such a 
positive person; Annika Ericsson for being a good friend and colleague. Pia Santesson, Natasha 
Widen, Enikö Fodor and Laili Singh, I wish you all success in your careers as endocrinologists! 
Joakim Bragd, colleague and friend, for the moments we shared during the ups and downs of 
writing a PhD thesis, and for your support. 
  52 
Nina Ringart, for helping in the practicalities of research work. 
Tim Crosfield, for being an excellent proofreader, and for your cooperation, especially during the 
hectic last weeks of my work. 
Agneta Söderbergh and Susan Öman, at Sanofi for support and for the production of placebo, 
without your contribution GLIM study would not have been possible to accomplish. 
All the staff at ASIH Lidingö, for working with me during the past year and supporting me in 
every possible way; especially during the last months of the thesis. Marita Lagergren Lindberg, 
my colleague, I look forward to helping when you go through the same journey as I have. 
All my dearest friends, no one mentioned, no one forgotten, for long being parts of my life and for 
lasting friendship. 
My sister-in-law, Carina, a rock of patience and kindness, helping me in many precious ways 
with big and small things. 
My sisters Ann-Sofi and Tina, and my father Kurt for true and deep support and for sharing many 
essentials of life! 
My beloved daughters Rebecka and Ebba: thank you for being so considerate and giving me the 
time needed to complete the work. You are the best part of my life and I am very proud of you. 
I’m now back to being a “real mum”! 
Danny, my dear husband for endless support and for taking care of our daughters, dogs, cats, and 
house in addition to your own busy work schedule… not forgetting all your delicious fruit salads. 
And finally Sunny and Thilda, our Springer Spaniels, that bring us so much happiness and fun. 
True devotion is what you are made of.  
  53 
REFERENCES 
Abbasi F, Lamendola C, Reaven GM. What is the effect of rosiglitazone treatment on insulin 
secretory function in insulin-resistant individuals? It depends on how you measure it. 
Metabolism 60: 57-62, 2011 
ADA. Standards of medical care in diabetes. Diabetes Care 35 (Suppl 1): S11-63, 2012 
Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency 
and risk factors of severe hypoglycaemia in insulin-treated Type 2 diabetes: a cross-sectional 
survey. Diabet Med 23: 750-56, 2006 
Al-Ozairi E, Sibal L, Home P. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): 
good for sulfonylureas? Diabetes Care 30: 1677-80, 2007 
Albareda M, Rigla M, Rodriguez-Espinosa J, Caballero A, Chico A, Cabezas R, Carreras G, 
Perez A. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. 
Diabetes Res Clin Pract 68: 202-6, 2005 
Albarrak AI, Luzio SD, Chassin LJ, Playle RA, Owens DR, Hovorka R. Associations of glucose 
control with insulin sensitivity and pancreatic beta-cell responsiveness in newly presenting 
type 2 diabetes. J Clin Endocrinol Metab 87: 198-203, 2002 
Alvarsson M, Sundkvist G, Lager I, Henricsson M, Berntorp K, Fernqvist-Forbes E, Steen L, 
Westermark G, Westermark P, Örn T, Grill V. Beneficial effects of insulin vs. sulphonylurea 
on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. 
Diabetes Care 26: 2231-37, 2003 
Amiel SA, Dixon T, Mann R, Jameson K. Hypoglycaemia in Type 2 diabetes.  
Diabet Med 25: 245-54, 2008 
Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM.  
Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin 
action and secretion that are maintained for two weeks after insulin withdrawal.  
Diabetes 33: 634-42, 1984 
Ashcroft SJ, Ashcroft FM. The sulfonylurea receptor. Biochim Biophys Acta 1175: 45-59, 1992 
Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, 
Puhan MA, Ranasinghe P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S. 
Comparative effectiveness and safety of medications for type 2 diabetes: an update including 
new drugs and 2-drug combinations. Ann Intern Med 154: 602-13, 2011 
Best JD, Drury PL, Davis TM, Taskinen MR, Kesaniemi YA, Scott R, Pardy C, Voysey M, 
Keech AC. Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world 
diabetes therapy in a clinical trial cohort. Diabetes Care 35: 1165-70, 2012 
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of 
clinical measurement. Lancet 1: 307-10, 1986 
Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of 
conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of 
continuous glucose sensing in pediatric patients with type 1 diabetes.  
Diabetes Care 24: 1858-62, 2001 
Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, 
Bass EB, Brancati FL. Systematic review: comparative effectiveness and safety of oral 
medications for type 2 diabetes mellitus. Ann Intern Med 147: 386-99, 2007 
  54 
Bragd J, Adamson U, Lins PE, Wredling R,Oskarsson P. A repeated cross-sectional survey of 
severe hypoglycaemia in 178 Type 1 diabetes mellitus patients performed in 1984 and 1998. 
Diabet Med 20: 216-19, 2003 
Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in 
older compared with middle-aged patients with type 2 diabetes.  
Diabetes Care 32: 1513-17, 2009 
Brierley EJ, Broughton DL, James OFAlberti KG. Reduced awareness of hypoglycaemia in the 
elderly despite an intact counter-regulatory response. QJM 88: 439-45, 1995 
Brown N. Is it time to re-assess the role of gliclazide? Targeting insulin resistance in type 2 
diabetes patients suboptimally controlled with insulin. Postgrad Med J 82: 471-75, 2006 
Brunzell JD, Robertson RP, Lerner RL, Hazzard WR, Ensinck JW, Bierman EL,Porte D, Jr. 
Relationships between fasting plasma glucose levels and insulin secretion during intravenous 
glucose tolerance tests. J Clin Endocrinol Metab 42: 222-9, 1976 
Buchanan TA. Pancreatic beta-cell loss and preservation in type 2 diabetes.  
Clin Ther 25 (Suppl B): B 32-46, 2003 
Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I.  
Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis.  
Am J Med 122: 248-56, 2009 
Bugos C, Austin M, Atherton TC. Viereck, C. Long-term treatment of type 2 diabetes mellitus 
with glimepiride is weight neutral: A meta-analysis.  
Diabetes Res Clin Pract 50 (Suppl 1): S47, 2000 
Butler AE, Janson J, Soeller WC, Butler PC. Increased beta-cell apoptosis prevents adaptive 
increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid 
formation rather than direct action of amyloid. Diabetes 52: 2304-14, 2003 
Caplin NJ, O'Leary P, Bulsara M, Davis EA, Jones TW. Subcutaneous glucose sensor values 
closely parallel blood glucose during insulin-induced hypoglycaemia.  
Diabet Med 20: 238-41, 2003 
Castillo M, Scheen AJ, Paolisso G, Lefebvre PJ. The addition of glipizide to insulin therapy in 
type-II diabetic patients with secondary failure to sulfonylureas is useful only in the presence 
of a significant residual insulin secretion. Acta Endocrinol (Copenh) 116: 364-72, 1987 
Chang AM, Halter JB. Aging and insulin secretion.  
Am J Physiol Endocrinol Metab 284: E7-12, 2003 
Chase HP, Kim LM, Owen SL, MacKenzie TA, Klingensmith GJ, Murtfeldt R, Garg SK. 
Continuous subcutaneous glucose monitoring in children with type 1 diabetes.  
Pediatrics 107: 222-6, 2001 
Chico A, Vidal-Rios P, Subira M, Novials A. The continuous glucose monitoring system is useful 
for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not 
better than frequent capillary glucose measurements for improving metabolic control.  
Diabetes Care 26: 1153-7, 2003 
Chlup R, Jelenova D, Chlupova K, Zapletalova J, Chlupova L, Bartek J. Function and accuracy  
of glucose sensors beyond their stated expiry date. Diabetes Technol Ther 8: 495-504, 2006 
Chow CC, Tsang LW, Sorensen JP, Cockram CS. Comparison of insulin with or without 
continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM 
patients. Diabetes Care 18: 307-14, 1995 
Clark A, Charge SB, Badman MK, de Koning EJ. Islet amyloid in type 2 (non-insulin-dependent) 
diabetes. APMIS 104: 12-18, 1996 
  55 
Clark CM, Jr., Helmy AW. Clinical trials with glimepiride. Drugs Today (Barc) 34: 401-8, 1998 
Clarke WL, Cox D, Gonder-Frederick LA, Carter W, Pohl SL. Evaluating clinical accuracy of 
systems for self-monitoring of blood glucose. Diabetes Care 10: 622-28, 1987 
Clauson P, Linnarsson R, Gottsäter A, Sundkvist G, Grill V. Relationships between diabetes 
duration, metabolic control and beta-cell function in a representative population of type 2 
diabetic patients in Sweden. Diabet Med 11: 794-801, 1994 
Clauson P, Karlander S, Steen L, Efendic S. Daytime glibenclamide and bedtime NPH insulin 
compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up. 
Diabet Med 13: 471-77, 1996 
Colagiuri S. Optimal management of type 2 diabetes: the evidence.  
Diabetes Obes Metab 14 (Suppl 1): 3-8, 2012 
DCCT. The effect of intensive treatment of diabetes on the development and progression of long-
term complications in insulin-dependent diabetes mellitus. The Diabetes Control and 
Complications Trial Research Group. N Engl J Med 329: 977-86, 1993 
DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin 
secretion and resistance. Am J Physiol 237: E214-23, 1979 
DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus.  
Ann Intern Med 131: 281-303, 1999 
Del Guerra S, Marselli L, Lupi R, Boggi U, Mosca F, Benzi L, Del Prato S, Marchetti P. Effects 
of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. 
J Diabetes Complications 19: 60-64, 2005 
Del Guerra S, Grupillo M, Masini M, Lupi R, Bugliani M, Torri S, Boggi U, Del Chiaro M, 
Vistoli F, Mosca F, Del Prato S, Marchetti P. Gliclazide protects human islet beta-cells from 
apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev 23: 234-38, 2007 
Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. 
Metabolism 55: S20-27, 2006 
Dills DG, Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-
blind comparative study. Glimepiride/Glyburide Research Group.  
Horm Metab Res 28: 426-9, 1996 
DirecNet Study Group. The accuracy of the CGMS in children with type 1 diabetes: results of the 
diabetes research in children network (DirecNet) accuracy study.  
Diabetes Technol Ther 5: 781-89, 2003 
Djakoure-Platonoff C, Radermercker R, Reach G, Slama G, Selam JI. Accuracy of the continuous 
glucose monitoring system in inpatient and outpatient conditions.  
Diabetes Metab 29: 159-62, 2003 
Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, Reinecke M. 
Mechanisms of beta-cell death in type 2 diabetes. Diabetes 54 (Suppl 2): S108-13, 2005 
Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R, Band MM, Reekie G, 
Leese GP. Frequency and predictors of hypoglycaemia in Type 1 and insulin-treated Type 2 
diabetes: a population-based study. Diabet Med 22: 749-55, 2005 
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J,  
Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, 
Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes.  
N Engl J Med 360: 129-39, 2009 
  56 
Ebato C, Shimizu T, Arakawa M, Mita T, Fujitani Y, Watada H, Kawamori R, Hirose T.  
Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): 
comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 
diabetic patients poorly controlled with sub-maximal glimepiride.  
Diabetes Res Clin Pract 86: 31-6, 2009 
Ekholm E, Gottsäter A, Dahlin LB, Sundkvist G. No signs of progressive beta cell damage  
during 20 years of prospective follow-up of autoantibody-negative diabetes.  
Acta Diabetol 49: 57-62, 2012 
Ekström N, Miftaraj M, Svensson AM, Andersson Sundell K, Cederholm J, Zethelius B, 
Gudbjörnsdottir S, Eliasson B. Glucose-lowering treatment and clinical results in 163 121 
patients with type 2 diabetes: an observational study from the Swedish national diabetes 
register. Diabetes Obes Metab 14: 717-26, 2012 
Engler RL, Yellon DM. Sulfonylurea KATP blockade in type II diabetes and preconditioning in 
cardiovascular disease. Time for reconsideration. Circulation 94: 2297-301, 1996 
Escobar-Jimenez F, Herrera Pombo JL, Gomez-Villalba R, Nunez del Carril J, Aguilar M,  
Rovira A. Standard breakfast test: an alternative to glucagon testing for C-peptide reserve? 
Horm Metab Res 22: 339-41, 1990 
Evans JM, Ogston SA, Emslie-Smith A, Morris AD. Risk of mortality and adverse cardiovascular 
outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and 
metformin. Diabetologia 49: 930-36, 2006 
Falko JM, Osei K. Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on 
lipoprotein metabolism and glucoregulation. Am J Med 79: 92-101, 1985 
Feinglos MN, Thacker CR, Lobaugh B, DeAtkine DD, McNeill DB, English JS, Bursey DL. 
Combination insulin and sulfonylurea therapy in insulin-requiring type 2 diabetes mellitus. 
Diabetes Res Clin Pract 39: 193-99, 1998 
Ferrannini E, Mari A. Beta cell function and its relation to insulin action in humans: a critical 
appraisal. Diabetologia 47: 943-56, 2004 
Frier BM. Hypoglycaemic valleys: an under-recognised problem in type 2 diabetes?  
Int J Clin Pract Suppl: 12-9, 2002 
Funakoshi S, Fujimoto S, Hamasaki A, Fujiwara H, Fujita Y, Ikeda K, Hamamoto Y, Hosokawa 
M, Seino Y, Inagaki N. Analysis of factors influencing pancreatic beta-cell function in 
Japanese patients with type 2 diabetes: association with body mass index and duration of 
diabetic exposure. Diabetes Res Clin Pract 82: 353-58, 2008 
Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on 
mortality in type 2 diabetes. N Engl J Med 358: 580-91, 2008 
Garg S, Zisser H, Schwartz S, Bailey T, Kaplan R, Ellis S, Jovanovic L. Improvement in 
glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized 
controlled trial. Diabetes Care 29: 44-50, 2006 
Gerritsen M. Problems associated with subcutaneously implanted glucose sensors.  
Diabetes Care 23: 143-45, 2000 
Gerstein HC, Miller ME, Byington RP, Goff DC, Jr., Bigger JT, Buse JB, Cushman WC, Genuth 
S, Ismail-Beigi F, Grimm RH, Jr., Probstfield JL, Simons-Morton DG, Friedewald WT.  
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-59, 2008 
Gjessing HJ, Damsgaard EM, Matzen LE, Froland A, Faber OK. Reproducibility of beta-cell 
function estimates in non-insulin-dependent diabetes mellitus. Diabetes Care 10: 558-62, 1987 
  57 
Gjessing HJ, Reinholdt B, Pedersen O. The plasma C-peptide and insulin responses to stimulation 
with intravenous glucagon and a mixed meal in well-controlled type 2 (non-insulin-dependent) 
diabetes mellitus: dependency on acutely established hyperglycaemia.  
Diabetologia 32: 858-63, 1989 
Glasgow RE, Peeples M, Skovlund SE. Where is the patient in diabetes performance measures? 
The case for including patient-centered and self-management measures.  
Diabetes Care 31: 1046-50, 2008 
Gotfredsen CF. Dynamics of sulfonylurea-induced insulin release from the isolated perfused rat 
pancreas. Diabetologia 12: 339-42, 1976 
Goudswaard AN, Stolk RP, Zuithoff P, de Valk HW, Rutten GE. Starting insulin in  
type 2 diabetes: continue oral hypoglycemic agents? A randomized trial in primary care.  
J Fam Pract 53: 393-99, 2004 
Gray A, Raikou M, McGuire A, Fenn P, Stevens R, Cull C, Stratton I, Adler A, Holman R, 
Turner R. Cost effectiveness of an intensive blood glucose control policy in patients with type 
2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United 
Kingdom Prospective Diabetes Study Group. BMJ 320: 1373-78, 2000 
Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. Secondary failure to treatment 
with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 9: 129-33, 1986 
Gross TM, Bode BW, Einhorn D, Kayne DM, Reed JH, White NH, Mastrototaro JJ. Performance 
evaluation of the MiniMed continuous glucose monitoring system during patient home use. 
Diabetes Technol Ther 2: 49-56, 2000 
Gross TM, Mastrototaro JJ. Efficacy and reliability of the continuous glucose monitoring system. 
Diabetes Technol Ther 2 (Suppl 1): S19-26, 2000 
Guerci B, Floriot M, Bohme P, Durain D, Benichou M, Jellimann S, Drouin P.  
Clinical performance of CGMS in type 1 diabetic patients treated by continuous subcutaneous 
insulin infusion using insulin analogs. Diabetes Care 26: 582-89, 2003 
Gutniak M, Karlander SG, Efendic S. Glyburide decreases insulin requirement, increases beta-cell 
response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term 
combined treatment in secondary failure to sulfonylurea. Diabetes Care 10: 545-54, 1987 
Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin secretion and increased 
insulin resistance are independently related to the 7-year risk of NIDDM in Mexican-
Americans. Diabetes 44: 1386-91, 1995 
Hanås R, John G. 2010 consensus statement on the worldwide standardization of the hemoglobin 
A1c measurement. Diabet Med 27: 737-38, 2010 
Hanefeld M, Koehler C, Hoffmann C, Wilhelm K, Kamke W, Gerstein H. Effect of targeting 
normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of 
hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.  
Diabet Med 27: 175-80, 2009 
Haupt E, Haupt A, Herrmann R, Benecke-Timp A, Vogel H, Walter C. The KID Study V:  
the natural history of type 2 diabetes in younger patients still practising a profession. 
Heterogeneity of basal and reactive C-peptide levels in relation to BMI, duration of disease, 
age and HbA1. Exp Clin Endocrinol Diabetes 107: 236-43, 1999 
Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled 
patients with type 2 diabetes mellitus: the results of continuous glucose monitoring.  
Diabetes Technol Ther 5: 19-26, 2003 
  58 
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J.  
Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-
analysis and trial sequential analysis of randomised clinical trials. BMJ 343: d6898, 2011 
Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycaemia in insulin-treated Type 2 diabetes: 
frequency, symptoms and impaired awareness. Diabet Med 20: 1016-21, 2003 
Hepburn DA, MacLeod KM, Pell AC, Scougal IJ, Frier BM. Frequency and symptoms of 
hypoglycaemia experienced by patients with type 2 diabetes treated with insulin.  
Diabet Med 10: 231-37, 1993 
Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of tests of beta-cell function across a 
range of glucose tolerance from normal to diabetes. Diabetes 48: 1779-86, 1999 
Hoenig M, Hall G, Ferguson D, Jordan K, Henson M, Johnson K, O'Brien T. A feline model of 
experimentally induced islet amyloidosis. Am J Pathol 157: 2143-50, 2000 
Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC. Addition of 
biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.  
N Engl J Med 357: 1716-30, 2007 
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive 
glucose control in type 2 diabetes. N Engl J Med 359: 1577-89, 2008 
Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with 
type 2 diabetes treated with glimepiride versus glibenclamide.  
Diabetes Metab Res Rev 17: 467-73, 2001 
Home P, Mant J, Diaz J, Turner C. Management of type 2 diabetes: summary of updated NICE 
guidance. BMJ 336: 1306-8, 2008 
Hostens K, Ling Z, Van Schravendijk C, Pipeleers D. Prolonged exposure of human beta-cells to 
high glucose increases their release of proinsulin during acute stimulation with glucose or 
arginine. J Clin Endocrinol Metab 84: 1386-90, 1999 
Hovorka R, Chassin L, Luzio SD, Playle R, Owens DR. Pancreatic beta-cell responsiveness 
during meal tolerance test: model assessment in normal subjects and subjects with newly 
diagnosed noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 83: 744-50, 1998 
Hovorka R, Albarrak A, Chassin L, Luzio SD, Playle R, Owens DR. Relationship between beta-
cell responsiveness and fasting plasma glucose in Caucasian subjects with newly presenting 
type 2 diabetes. Diabet Med 18: 797-802, 2001 
IDF. International Diabetes Federation. Global Guidelines for type 2 diabetes. 2006 
IDF. International Diabetes Federation. Diabetes Atlas, 3rd edition., 2008 
IDF. International Diabetes Federation. Diabetes Atlas, 5th edition. 2011 
IFCC. Consensus statement on the worldwide standardisation of the HbA1c measurement. 
Diabetologia 50: 2042-3, 2007 
Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review.  
JAMA 287: 360-72, 2002 
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, 
Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered 
approach: position statement of the American Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD). Diabetes Care 35: 1364-79, 2012 
Iscoe KE, Davey RJ, Fournier PA. Is the response of continuous glucose monitors to 
physiological changes in blood glucose levels affected by sensor life?  
Diabetes Technol Ther 14: 135-42, 2012 
  59 
Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing 
glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.  
Ann Intern Med 154: 554-59, 2011 
Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people 
aged 65 years and older: a systematic review. Drugs Aging 25: 1021-31, 2008 
Jaap AJ, Jones GC, McCrimmon RJ, Deary IJ, Frier BM. Perceived symptoms of hypoglycaemia 
in elderly type 2 diabetic patients treated with insulin. Diabet Med 15: 398-401, 1998 
Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison 
of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin 
therapy for type 2 diabetes. Diabetes Care 28: 254-59, 2005 
Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus 
premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.  
J Am Geriatr Soc 55: 182-88, 2007 
Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in 
type II diabetes. A meta-analysis of the randomized placebo-controlled trials.  
Arch Intern Med 156: 259-64, 1996 
Jonsson A, Rydberg T, Ekberg G, Hallengren B, Melander A. Slow elimination of glyburide in 
NIDDM subjects. Diabetes Care 17: 142-45, 1994 
Jonsson A, Hallengren B, Rydberg T, Melander A. Effects and serum levels of glibenclamide and 
its active metabolites in patients with type 2 diabetes. Diabetes Obes Metab 3: 403-9, 2001 
Kabadi MUKabadi UM. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus.  
Ann Pharmacother 37: 1572-76, 2003 
Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, 
Ward WK, Beard JC, Palmer JP. Quantification of the relationship between insulin sensitivity 
and beta-cell function in human subjects. Evidence for a hyperbolic function.  
Diabetes 42: 1663-72, 1993 
Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, 
O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or 
glyburide monotherapy. N Engl J Med 355: 2427-43, 2006 
Kahn SE, Carr DB, Faulenbach MV, Utzschneider KM. An examination of beta-cell function 
measures and their potential use for estimating beta-cell mass.  
Diabetes Obes Metab 10 (Suppl 4): 63-76, 2008 
Karaca M, Magnan C, Kargar C. Functional pancreatic beta-cell mass: involvement in type 2 
diabetes and therapeutic intervention. Diabetes Metab 35: 77-84, 2009 
Khunti K. Personal communication. (2012) 
Klepzig H, Kober G, Matter C, Luus H, Schneider H, Boedeker KH, Kiowski W, Amann FW, 
Gruber D, Harris S, Burger W. Sulfonylureas and ischaemic preconditioning; a double-blind, 
placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 20: 439-46, 1999 
Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy.  
Diabetes Care 28: 1231-9, 2005 
Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. 
adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 27: 17-20, 2004 
Korytkowski MT. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. 
Pharmacotherapy 24: 606-20, 2004 
  60 
Koskinen PJ, Viikari JS, Irjala KM. Glucagon-stimulated and postprandial plasma C-peptide 
values as measures of insulin secretory capacity. Diabetes Care 11: 318-22, 1988 
Kramer W, Muller G, Geisen K. Characterization of the molecular mode of action of the 
sulfonylurea, glimepiride, at beta-cells. Horm Metab Res 28: 464-68, 1996 
Kubiak T, Hermanns N, Schreckling HJ, Kulzer B, Haak T. Assessment of hypoglycaemia 
awareness using continuous glucose monitoring. Diabet Med 21: 487-90, 2004 
Läkemedelsverket. Läkemedelsbehandling vid typ 2-diabetes - rekommendation. 2010 
Landin-Olsson M. Latent autoimmune diabetes in adults. Ann N Y Acad Sci 958: 112-16, 2002 
Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins PE. Comparison of bedtime NPH or 
preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. 
Diabetes Care 18: 1183-86, 1995 
Landstedt-Hallin L, Arner P, Lins PE, Bolinder J, Olsen H, Groop L. The role of sulphonylurea in 
combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-
Sulphonylurea Study Group Research Team. Diabet Med 16: 827-34, 1999 
Leahy JL, Bonner-Weir S, Weir GC. Beta-cell dysfunction induced by chronic hyperglycemia. 
Current ideas on mechanism of impaired glucose-induced insulin secretion.  
Diabetes Care 15: 442-55, 1992 
Leahy JL. Pathogenesis of type 2 diabetes mellitus. Arch Med Res 36: 197-209, 2005 
Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting beta-cell function early in the course 
of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 95: 4206-16, 2010 
Lebovitz HE, Pasmantier R. Combination insulin-sulfonylurea therapy.  
Diabetes Care 13: 667-75, 1990 
Lebovitz HE. Insulin: potential negative consequences of early routine use in patients with type 2 
diabetes. Diabetes Care 34 (Suppl 2): S225-30, 2011 
Leese GP, Wang J, Broomhall J, Kelly P, Marsden A, Morrison W, Frier BM, Morris AD. 
Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 
diabetes: a population-based study of health service resource use.  
Diabetes Care 26: 1176-80, 2003 
Leibowitz G, Cerasi E. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: 
a mixed blessing? Diabetologia 39: 503-14, 1996 
Lev-Ran A, Yerushalmy Y, Weissglas L, Pertsis V, Ishay JS, Hwang DL. In most poorly 
controlled glyburide-treated type 2 diabetic patients drug withdrawal causes further increase in 
glycemia not accompanied by changes in insulin secretion. Horm Metab Res 30: 108-10, 1998 
Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the 
onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus:  
the 10-year follow-up of the Belfast Diet Study. Diabet Med 15: 290-96, 1998 
Lewitt MS, Yu VK, Rennie GC, Carter JN, Marel GM, Yue DK, Hooper MJ. Effects of combined 
insulin-sulfonylurea therapy in type II patients. Diabetes Care 12: 379-83, 1989 
Lindström T, Arnqvist HJ, Ludvigsson J, von Schenck HH. C-peptide profiles in patients with  
non-insulin-dependent diabetes mellitus before and during insulin treatment.  
Acta Endocrinol (Copenh) 126: 477-83, 1992 
Little RR, Rohlfing CL, Sacks DB. Status of hemoglobin A1c measurement and goals for 
improvement: from chaos to order for improving diabetes care. Clin Chem 57: 205-14, 2011 
  
  61 
Lyssenko V, Almgren P, Anevski D, Perfekt R, Lahti K, Nissen M, Isomaa B, Forsen B, 
Homstrom N, Saloranta C, Taskinen MR, Groop L, Tuomi T. Predictors of and longitudinal 
changes in insulin sensitivity and secretion preceding onset of type 2 diabetes.  
Diabetes 54: 166-74, 2005 
Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-
cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90: 501-6, 2005 
Mäkimattila S, Nikkila K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and 
without metformin in patients with Type II diabetes mellitus. Diabetologia 42: 406-12, 1999 
Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular 
disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical 
trials. Nutr Metab Cardiovasc Dis 19: 604-12, 2009 
Mari A, Tura A, Gastaldelli A, Ferrannini E. Assessing insulin secretion by modeling in multiple-
meal tests: role of potentiation. Diabetes 51 (Suppl 1): S221-26, 2002 
Maruyama T, Tanaka S, Shimada A, Funae O, Kasuga A, Kanatsuka A, Takei I, Yamada S, Harii 
N, Shimura H, Kobayashi T. Insulin intervention in slowly progressive insulin-dependent (type 
1) diabetes mellitus. J Clin Endocrinol Metab 93: 2115-21, 2008 
Massi-Benedetti M, Orsini-Federici M. Treatment of type 2 diabetes with combined therapy:  
what are the pros and cons? Diabetes Care 31 (Suppl 2): S131-5, 2008 
Mastrototaro J, Shin J, Marcus A, Sulur G. The accuracy and efficacy of real-time continuous 
glucose monitoring sensor in patients with type 1 diabetes.  
Diabetes Technol Ther 10: 385-90, 2008 
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC.  
Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma 
glucose and insulin concentrations in man. Diabetologia 28: 412-19, 1985 
Matthews DR, Cull CA, Stratton IM, Holman RRTurner RC. UKPDS 26: Sulphonylurea failure 
in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study 
(UKPDS) Group. Diabet Med 15: 297-303, 1998 
Matyka K, Evans M, Lomas J, Cranston I, Macdonald I, Amiel SA. Altered hierarchy of 
protective responses against severe hypoglycemia in normal aging in healthy men.  
Diabetes Care 20: 135-41, 1997 
McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes.  
Diabet Med 18: 690-705, 2001 
McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA.  
Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is 
associated with recovery of beta cell function. Diabet Med 18: 10-16, 2001 
McGowan K, Thomas W, Moran A. Spurious reporting of nocturnal hypoglycemia by CGMS  
in patients with tightly controlled type 1 diabetes. Diabetes Care 25: 1499-503, 2002 
McNally PG, Dean JD, Morris AD, Wilkinson PD, Compion G, Heller SR. Using continuous 
glucose monitoring to measure the frequency of low glucose values when using biphasic 
insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in 
individuals with type 2 diabetes. Diabetes Care 30: 1044-48, 2007 
Meier JJ, Menge BA, Breuer TG, Muller CA, Tannapfel A, Uhl W, Schmidt WE, Schrader H. 
Functional assessment of pancreatic beta-cell area in humans. Diabetes 58: 1595-603, 2009 
Melander A, Lebovitz HE, Faber OK. Sulfonylureas. Why, which, and how?  
Diabetes Care 13 (Suppl 3): 18-25, 1990 
  62 
Miller CD, Phillips LS, Ziemer DC, Gallina DL, Cook CB, El-Kebbi IM. Hypoglycemia in 
patients with type 2 diabetes mellitus. Arch Intern Med 161: 1653-59, 2001 
Monsod TP, Flanagan DE, Rife F, Saenz R, Caprio S, Sherwin RS, Tamborlane WV.  
Do sensor glucose levels accurately predict plasma glucose concentrations during 
hypoglycemia and hyperinsulinemia? Diabetes Care 25: 889-93, 2002 
Mutch WJ, Dingwall-Fordyce I. Is it a hypo? Knowledge of the symptoms of hypoglycaemia in 
elderly diabetic patients. Diabet Med 2: 54-56, 1985 
Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B.  
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for 
the initiation and adjustment of therapy: a consensus statement from the American Diabetes 
Association and the European Association for the Study of Diabetes.  
Diabetologia 52: 17-30, 2009 
Niskanen L, Karjalainen J, Siitonen O, Uusitupa M. Metabolic evolution of type 2 diabetes:  
a 10-year follow-up from the time of diagnosis. J Intern Med 236: 263-70, 1994 
Nobels F, Van Gaal L, Rillaerts E, De Leeuw I. Effect of oral antidiabetic drug withdrawal in  
type 2 diabetes. Diabet Med 6: 149-51, 1989 
Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS. Prevalence, treatment,  
and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination 
Survey 1999-2004. Ann Epidemiol 18: 222-29, 2008 
Ose H, Fukui M, Kitagawa Y, Hirata C, Ichio N, Kadono M, Mogami S, Onishi M, Ichida Y, 
Nakajima T, Hasegawa G, Yoshikawa T, Nakamura N. Efficacy of glimepiride in patients  
with poorly controlled insulin-treated type 2 diabetes mellitus. Endocr J. 52: 563-69, 2005 
Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Nutter B, Jain A, Atreja A,  
Zimmerman RS. The risk of overall mortality in patients with Type 2 diabetes receiving 
different combinations of sulfonylureas and metformin: a retrospective analysis.  
Diabet Med 29: 1029-35, 2012 
Parkes JL, Slatin SL, Pardo S, Ginsberg BH. A new consensus error grid to evaluate the clinical 
significance of inaccuracies in the measurement of blood glucose.  
Diabetes Care 23: 1143-48, 2000 
Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, 
Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE,  
Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F.  
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.  
N Engl J Med 358: 2560-72, 2008 
Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jorgensen HV, 
Matthews DR, Hougaard P, Thorsteinsson B. Severe hypoglycaemia in 1076 adult patients 
with type 1 diabetes: influence of risk markers and selection.  
Diabetes Metab Res Rev 20: 479-86, 2004 
Pegg A, Fitzgerald F, Wise D, Singh BM, Wise PH. A community-based study of diabetes-related 
skills and knowledge in elderly people with insulin-requiring diabetes.  
Diabet Med 8: 778-81, 1991 
Peters AL. Davidson MB. Insulin plus a sulfonylurea agent for treating type 2 diabetes.  
Ann Intern Med 115: 45-53, 1991 
  
  63 
Pfutzner A, Lorra B, Abdollahnia MR, Kann PH, Mathieu D, Pehnert C, Oligschleger C,  
Kaiser M, Forst T. The switch from sulfonylurea to preprandial short-acting insulin analog 
substitution has an immediate and comprehensive beta-cell protective effect in patients with 
type 2 diabetes mellitus. Diabetes Technol Ther 8: 375-84, 2006 
Poitout V. Robertson RP. Minireview: Secondary beta-cell failure in type 2 diabetes  
- a convergence of glucotoxicity and lipotoxicity. Endocrinology 143: 339-42, 2002 
Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent 
autoimmune diabetes of the adult): definition, characterization, and potential prevention. 
Diabetes Care 24: 1460-67, 2001 
Pugh JA, Wagner ML, Sawyer J, Ramirez G, Tuley M, Friedberg SJ. Is combination sulfonylurea 
and insulin therapy useful in NIDDM patients? A metaanalysis.  
Diabetes Care 15: 953-59, 1992 
Rachman J, Payne MJ, Levy JC, Barrow BA, Holman RR, Turner RC. Changes in amylin and 
amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin 
therapy in NIDDM. Diabetes Care 21: 810-16, 1998 
Raptis SA, Hatziagelaki E, Dimitriadis G, Draeger KE, Pfeiffer C, Raptis AE. Comparative 
effects of glimepiride and glibenclamide on blood glucose, C-peptide and insulin 
concentrations in the fasting and postprandial state in normal man.  
Exp Clin Endocrinol Diabetes 107: 350-55, 1999 
Raskin P. Why insulin sensitizers but not secretagogues should be retained when initiating insulin 
in type 2 diabetes. Diabetes Metab Res Rev 24: 3-13, 2008 
Ravnik-Oblak M, Mrevlje F. Insulin versus a combination of insulin and sulfonylurea in the 
treatment of NIDDM patients with secondary oral failure.  
Diabetes Res Clin Pract 30: 27-35, 1995 
Reaven GM. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes 
characterised by a progressive and inexorable loss of insulin secretory function? Maybe? 
Maybe not? Diab Vasc Dis Res 6: 133-38, 2009 
Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus.  
Drugs 64: 1339-58, 2004 
Riddle M, Gard T, Hart J. A new regimen for type II diabetes. Bedtime NPH insulin with day-
time sulfonylure [abstract]. Diabetes 33 (Suppl 1): 182A, 1984 
Riddle MC, Hart JS, Bouma DJ, Phillipson BE, Youker G. Efficacy of bedtime NPH insulin with 
daytime sulfonylurea for subpopulation of type II diabetic subjects.  
Diabetes Care 12: 623-29, 1989 
Riddle MC, Garrison C, McDaniel P, Goldberg L. Combined therapy versus insulin alone for  
type 2 diabetes: diurnal patterns and respons to exercise [abstract].  
Diabetes 41 (Suppl 1): 192A, 1992 
Riddle MC, Schneider J. Beginning insulin treatment of obese patients with evening 70/30 insulin 
plus glimepiride versus insulin alone. Glimepiride Combination Group.  
Diabetes Care 21: 1052-57, 1998 
Riddle MC. More reasons to say goodbye to glyburide.  
J Clin Endocrinol Metab 95: 4867-70, 2010 
Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and 
safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. 
Diabetologia 39: 1617-24, 1996 
  64 
Sachedina N, Pickup JC. Performance assessment of the Medtronic-MiniMed Continuous 
Glucose Monitoring System and its use for measurement of glycaemic control in Type 1 
diabetic subjects. Diabet Med 20: 1012-15, 2003 
Sawada F, Inoguchi T, Tsubouchi H, Sasaki S, Fujii M, Maeda Y, Morinaga H, Nomura M, 
Kobayashi K, Takayanagi R. Differential effect of sulfonylureas on production of reactive 
oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6.  
Metabolism 57: 1038-45, 2008 
Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL. Postchallenge hyperglycemia and 
mortality in a national sample of U.S. adults. Diabetes Care 24: 1397-402, 2001 
Scheen AJ. Diabetes mellitus in the elderly: insulin resistance and/or impaired insulin secretion? 
Diabetes Metab 31 (Spec No 2): 5S27-5S34, 2005 
Scholz GH, Schneider K, Knirsch W, Becker G. Efficacy and Tolerability of Glimepiride in Daily 
Practice: A Non-Interventional Observational Cohort Study.  
Clin Drug Invest. 21: 597-604, 2001 
Schopman JE, Geddes J, Frier BM. Prevalence of impaired awareness of hypoglycaemia and 
frequency of hypoglycaemia in insulin-treated type 2 diabetes.  
Diabetes Res Clin Pract 87: 64-8, 2011 
Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbol EL, Kober L, 
Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Mortality and cardiovascular risk 
associated with different insulin secretagogues compared with metformin in type 2 diabetes, 
with or without a previous myocardial infarction: a nationwide study.  
Eur Heart J 32: 1900-8, 2011 
Schwartz NS, Clutter WE, Shah SD, Cryer PE. Glycemic thresholds for activation of glucose 
counterregulatory systems are higher than the threshold for symptoms.  
J Clin Invest 79: 777-81, 1987 
Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 
2 diabetes. Diabetes 51: 724-33, 2002 
Service FJ. Hypoglycemia. Med Clin North Am 79: 1-8, 1995 
Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide. Effective therapy for 
sulfonylurea failures in NIDDM. Diabetes 44: 165-72, 1995 
Sherifali D, Nerenberg K, Pullenayegum E, Cheng JE, Gerstein HC. The effect of oral 
antidiabetic agents on A1C levels: a systematic review and meta-analysis.  
Diabetes Care 33: 1859-64, 2010 
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on 
optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 (Suppl 2): B21-29, 2000 
Shim WS, Kim SK, Kim HJ, Kang ES, Ahn CW, Lim SK, Lee HC, Cha BS. Decrement of 
postprandial insulin secretion determines the progressive nature of type-2 diabetes.  
Eur J Endocrinol 155: 615-22, 2006 
Shorr RI, Ray WA, Daugherty JR, Griffin MR. Incidence and risk factors for serious 
hypoglycemia in older persons using insulin or sulfonylureas.  
Arch Intern Med 157: 1681-86, 1997 
Simpson SH, Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation 
between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based 
cohort study. CMAJ 174: 169-74, 2006 
  65 
Smith RJ, Nathan DM, Arslanian SA, Groop L, Rizza RA, Rotter JI. Individualizing therapies in 
type 2 diabetes mellitus based on patient characteristics: what we know and what we need to 
know. J Clin Endocrinol Metab 95: 1566-74, 2010 
Socialstyrelsen. Nationella Riktlinjer för Diabetesvården. 2010 
Stone MA, Wilkinson JC, Charpentier G, Clochard N, Grassi G, Lindblad U, Muller UA, Nolan J, 
Rutten GE, Khunti K. Evaluation and comparison of guidelines for the management of people 
with type 2 diabetes from eight European countries. Diabetes Res Clin Pract 87: 252-60, 2010 
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, 
Holman RR. Association of glycaemia with macrovascular and microvascular complications of 
type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-12, 2000 
Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and 
therapy. Lancet 365:1333-46, 2005 
ter Braak EW, Appelman AM, van de Laak M, Stolk RP, van Haeften TW, Erkelens DW. 
Clinical characteristics of type 1 diabetic patients with and without severe hypoglycemia. 
Diabetes Care 23: 1467-71, 2000 
TLV. Genomgången av läkemedel vid diabetes (2010). 
Trischitta V, Italia S, Raimondo M, Guardabasso V, Licciardello C, Runello F, Mazzarino S, 
Sangiorgi L, Anello M, Vigneri R. Efficacy of combined treatments in NIDDM patients with 
secondary failure to sulphonylureas. Is it predictable? J Endocrinol Invest 21: 744-47, 1998 
Tsumura K. Clinical evaluation of glimepiride (HOE490) in NIDDM, including a double blind 
comparative study versus gliclazide. Diabetes Res Clin Pract 28 (Suppl): S147-49, 1995 
Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnström BO,  
Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR. Groop LC.  
Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies.  
Diabetes 48: 150-7, 1999 
Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, 
Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase 
for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. 
Lancet 350: 1288-93, 1997 
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, 
or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple 
therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.  
JAMA 281: 2005-12, 1999 
UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of 
treatment modalities and their duration. Diabetologia 50: 1140-47, 2007 
UKPDS. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a 
progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 44: 1249-58, 1995 
UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with 
conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). 
UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837-53, 1998 
Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical 
implications. Diabetes 44: 863-70, 1995 
van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas.  
J Clin Epidemiol 50: 735-41, 1997 
  66 
Weber KK, Lohmann T, Busch K, Donati-Hirsch I, Riel R. High frequency of unrecognized 
hypoglycaemias in patients with Type 2 diabetes is discovered by continuous glucose 
monitoring. Exp Clin Endocrinol Diabetes 115: 491-94, 2007 
Weitgasser R, Lechleitner M, Luger A, Klingler A. Effects of glimepiride on HbA1c and body 
weight in Type 2 diabetes: results of a 1.5-year follow-up study.  
Diabetes Res Clin Pract 61: 13-19, 2003 
Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and 
diabetes mellitus. Physiol Rev 91: 795-826, 2011 
Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction 
and insulin resistance in the pathogenesis of type 2 diabetes mellitus.  
J Clin Invest 104: 787-94, 1999 
Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence 
of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311-21, 2011 
Wong LJ, Buckingham BA, Kunselman B, Istoc E, Leach J, Purvis R. Extended use of a new 
continuous glucose monitoring system with wireless data transmission in children with type 1 
diabetes mellitus. Diabetes Technol Ther 8: 139-45, 2006 
Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of 
addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective 
Diabetes Study (UKPDS 57). Diabetes Care 25: 330-36, 2002 
Yki-Järvinen H, Ryysy L, Nikkilaä K, Tulokas T, Vanamo R, Heikkilä M. Comparison of 
bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled 
trial. Ann Intern Med 130: 389-96, 1999 
Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes.  
Diabetes Care 24: 758-67, 2001 
Yki-Järvinen H. ADOPT: lessons from comparison of glycemic durability of rosiglitazone, 
metformin, or glyburide monotherapy. Curr Diab Rep 7: 173-74, 2007 
Yokoyama H, Sone H, Yamada D, Honjo J, Haneda M. Contribution of glimepiride to basal-
prandial insulin therapy in patients with type 2 diabetes.  
Diabetes Res Clin Pract 91: 148-53, 2010 
Yudkin JS, Richter B, Gale EA. Intensified glucose lowering in type 2 diabetes: time for a 
reappraisal. Diabetologia 53: 2079-85, 2010 
Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and 
effects of different treatment modalities. Diabetes Care 28: 2948-61, 2005 
Zangeneh F, Arora PS, Dyck PJ, Bekris L, Lernmark A, Achenbach SJ, Oberg AL, Rizza RA. 
Effects of duration of type 2 diabetes mellitus on insulin secretion.  
Endocr Pract 12: 388-93, 2006 
Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, Berland J, Gueret P, Wyart P, 
Deturck R, Tabone X, Machecourt J, Leclercq F, Drouet E, Mulak G, Bataille V, Cambou JP, 
Ferrieres J, Simon T. Impact of type of preadmission sulfonylureas on mortality and cardio-
vascular outcomes in diabetic patients with acute myocardial infarction.  
J Clin Endocrinol Metab 95: 4993-5002, 2010 
Zhang CY, Sun AJ, Zhang SN, Wu CN, Fu MQ, Xia G, Wang KQ, Zou YZ, Ge JB. Effects of 
intensive glucose control on incidence of cardiovascular events in patients with type 2 
diabetes: a meta-analysis. Ann Med 42: 305-15, 2009 
  67 
Zick R, Petersen B, Richter M, Haug C. Comparison of continuous blood glucose measurement 
with conventional documentation of hypoglycemia in patients with Type 2 diabetes on 
multiple daily insulin injection therapy. Diabetes Technol Ther 9: 483-92, 2007 
Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 26: 511-22, 1997 
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic.  
Nature 414: 782-7, 2001 
 
